
<html lang="en"     class="pb-page"  data-request-id="94723be3-f1c0-4e18-8c1c-b17fe19ea09a"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/jm200712h;issue:issue:10.1021/jmcmar.2011.54.issue-20;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Design, Synthesis, and Evaluation of a Novel Dual Fms-Like Tyrosine Kinase 3/Stem Cell Factor Receptor (FLT3/c-KIT) Inhibitor for the Treatment of Acute Myelogenous Leukemia" /></meta><meta name="dc.Creator" content="Robert J.  Davies" /></meta><meta name="dc.Creator" content="Albert C.  Pierce" /></meta><meta name="dc.Creator" content="Cornelia  Forster" /></meta><meta name="dc.Creator" content="Ron  Grey" /></meta><meta name="dc.Creator" content="Jinwang  Xu" /></meta><meta name="dc.Creator" content="Michael  Arnost" /></meta><meta name="dc.Creator" content="Deborah  Choquette" /></meta><meta name="dc.Creator" content="Vincent  Galullo" /></meta><meta name="dc.Creator" content="Shi-Kai  Tian" /></meta><meta name="dc.Creator" content="Greg  Henkel" /></meta><meta name="dc.Creator" content="Guanjing  Chen" /></meta><meta name="dc.Creator" content="David K.  Heidary" /></meta><meta name="dc.Creator" content="Joanne  Ma" /></meta><meta name="dc.Creator" content="Cameron  Stuver-Moody" /></meta><meta name="dc.Creator" content="Mark  Namchuk" /></meta><meta name="dc.Description" content="A high-throughput screen of our compound archive revealed a novel class of dual FMS-like tyrosine kinase 3 (FLT3)/c-KIT inhibitors. With the help of molecular modeling, this class was rapidly optim..." /></meta><meta name="Description" content="A high-throughput screen of our compound archive revealed a novel class of dual FMS-like tyrosine kinase 3 (FLT3)/c-KIT inhibitors. With the help of molecular modeling, this class was rapidly optim..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="October 4, 2011" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm200712h" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2011 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm200712h" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm200712h" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm200712h" /></link>
        
    
    

<title>Design, Synthesis, and Evaluation of a Novel Dual Fms-Like Tyrosine Kinase 3/Stem Cell Factor Receptor (FLT3/c-KIT) Inhibitor for the Treatment of Acute Myelogenous Leukemia | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm200712h" /></meta><meta property="og:title" content="Design, Synthesis, and Evaluation of a Novel Dual Fms-Like Tyrosine Kinase 3/Stem Cell Factor Receptor (FLT3/c-KIT) Inhibitor for the Treatment of Acute Myelogenous Leukemia" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-20/jm200712h/production/images/large/jm-2011-00712h_0006.jpeg" /></meta><meta property="og:description" content="A high-throughput screen of our compound archive revealed a novel class of dual FMS-like tyrosine kinase 3 (FLT3)/c-KIT inhibitors. With the help of molecular modeling, this class was rapidly optimized for both potency against FLT3 and FLT3/c-KIT and excellent potency in cell-based assays, leading to dose-dependent cell death in acute myelogenous leukemia (AML) patient blast samples. Ultimately, the AML patient blast data defined the preferred target profile as we designed and evaluated a set of FLT3 selective and FLT3/c-KIT dual molecules. Further optimization for pharmacokinetic properties resulted in the selection of the dual FLT3/c-KIT inhibitor, N3-(4-(trans-4-morpholinocyclohexyl)phenyl)-1-(pyridin-2-yl)-1H-1,2,4-triazole-3,5-diamine, VX-322 (compound 37), to move forward to preclinical evaluation." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="A high-throughput screen of our compound archive revealed a novel class of dual FMS-like tyrosine kinase 3 (FLT3)/c-KIT inhibitors. With the help of molecular modeling, this class was rapidly optimized for both potency against FLT3 and FLT3/c-KIT and excellent potency in cell-based assays, leading to dose-dependent cell death in acute myelogenous leukemia (AML) patient blast samples. Ultimately, the AML patient blast data defined the preferred target profile as we designed and evaluated a set of FLT3 selective and FLT3/c-KIT dual molecules. Further optimization for pharmacokinetic properties resulted in the selection of the dual FLT3/c-KIT inhibitor, N3-(4-(trans-4-morpholinocyclohexyl)phenyl)-1-(pyridin-2-yl)-1H-1,2,4-triazole-3,5-diamine, VX-322 (compound 37), to move forward to preclinical evaluation." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-20/jm200712h/production/images/large/jm-2011-00712h_0006.jpeg" /></meta><meta name="twitter:title" content="Design, Synthesis, and Evaluation of a Novel Dual Fms-Like Tyrosine Kinase 3/Stem Cell Factor Receptor (FLT3/c-KIT) Inhibitor for the Treatment of Acute Myelogenous Leukemia" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm200712h"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm200712h">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm200712h&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm200712h&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm200712h&amp;href=/doi/10.1021/jm200712h" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2011</span><span class="cit-fg-volume">, 54</span><span class="cit-fg-issue">, 20</span><span class="cit-fg-pageRange">, 7184-7192</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/54/20" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm200778q" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm200782y" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design, Synthesis, and Evaluation of a Novel Dual Fms-Like Tyrosine Kinase 3/Stem Cell Factor Receptor (FLT3/c-KIT) Inhibitor for the Treatment of Acute Myelogenous Leukemia</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Robert+J.++Davies">Robert J. Davies</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Albert+C.++Pierce">Albert C. Pierce</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Cornelia++Forster">Cornelia Forster</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ron++Grey">Ron Grey</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jinwang++Xu">Jinwang Xu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Arnost">Michael Arnost</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Deborah++Choquette">Deborah Choquette</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Vincent++Galullo">Vincent Galullo</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shi-Kai++Tian">Shi-Kai Tian</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Greg++Henkel">Greg Henkel</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Guanjing++Chen">Guanjing Chen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=David+K.++Heidary">David K. Heidary</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∇</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Joanne++Ma">Joanne Ma</a></span><span class="author-xref-symbol author-aff-symbol"><sup>+</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Cameron++Stuver-Moody">Cameron Stuver-Moody</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark++Namchuk">Mark Namchuk</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Vertex Pharmaceuticals Inc., 130 Waverly Street, Cambridge, Massachusetts 02139, United States</span></div><div class="aff-info" id="aff2"><span class="aff-text">Novartis IBMR, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div><div class="aff-info" id="aff3"><span class="aff-text">Amgen, 1 Kendall Square, Cambridge, Massachusetts 02139, United States</span></div><div class="aff-info" id="aff4"><span class="aff-text">Astra Zeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div><div class="aff-info" id="aff5"><span class="aff-text">University of Science & Technology of China, Hefei, Anhui 230026, China</span></div><div class="aff-info" id="aff6"><span class="aff-text">Arisan Therapeutics, 21512 Canaria, Mission Viejo, California 92692, United States</span></div><div class="aff-info" id="aff7"><span class="aff-text">University of Kentucky, Lexington, Kentucky 40506, United States</span></div><div class="aff-info" id="aff8"><span class="aff-text">Merck West Point, 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States</span></div><div class="corresp-info">Tel: 617-444-6506. E-mail: <a href="/cdn-cgi/l/email-protection#03716c616671775c6762756a6670437571777b2d606c6e"><span class="__cf_email__" data-cfemail="60120f020512143f04011609051320161214184e030f0d">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm200712h&amp;href=/doi/10.1021%2Fjm200712h" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2011</span></span><span class="cit-volume">, 54</span><span class="cit-issue">, 20</span><span class="cit-pageRange">, 7184–7192</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">October 4, 2011</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>16 June 2011</li><li><span class="item_label"><b>Published</b> online</span>4 October 2011</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 27 October 2011</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm200712h" title="DOI URL">https://doi.org/10.1021/jm200712h</a></div><div class="article_header-article-copyright"><strong>Copyright © 2011 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D7184%26pageCount%3D9%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DRobert%2BJ.%2BDavies%252C%2BAlbert%2BC.%2BPierce%252C%2BCornelia%2BForster%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D54%26issueNum%3D20%26contentID%3Djm200712h%26title%3DDesign%252C%2BSynthesis%252C%2Band%2BEvaluation%2Bof%2Ba%2BNovel%2BDual%2BFms-Like%2BTyrosine%2BKinase%2B3%252FStem%2BCell%2BFactor%2BReceptor%2B%2528FLT3%252Fc-KIT%2529%2BInhibitor%2Bfor%2Bthe%2BTreatment%2Bof%2BAcute%2BMyelogenous%2BLeukemia%26numPages%3D9%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D7192%26publicationDate%3DOctober%2B2011">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm200712h"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2436</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">14</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm200712h" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design, Synthesis, and Evaluation of a Novel Dual Fms-Like Tyrosine Kinase 3/Stem Cell Factor Receptor (FLT3/c-KIT) Inhibitor for the Treatment of Acute Myelogenous Leukemia&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;J. Davies&quot;},{&quot;first_name&quot;:&quot;Albert&quot;,&quot;last_name&quot;:&quot;C. Pierce&quot;},{&quot;first_name&quot;:&quot;Cornelia&quot;,&quot;last_name&quot;:&quot;Forster&quot;},{&quot;first_name&quot;:&quot;Ron&quot;,&quot;last_name&quot;:&quot;Grey&quot;},{&quot;first_name&quot;:&quot;Jinwang&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Arnost&quot;},{&quot;first_name&quot;:&quot;Deborah&quot;,&quot;last_name&quot;:&quot;Choquette&quot;},{&quot;first_name&quot;:&quot;Vincent&quot;,&quot;last_name&quot;:&quot;Galullo&quot;},{&quot;first_name&quot;:&quot;Shi-Kai&quot;,&quot;last_name&quot;:&quot;Tian&quot;},{&quot;first_name&quot;:&quot;Greg&quot;,&quot;last_name&quot;:&quot;Henkel&quot;},{&quot;first_name&quot;:&quot;Guanjing&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;K. Heidary&quot;},{&quot;first_name&quot;:&quot;Joanne&quot;,&quot;last_name&quot;:&quot;Ma&quot;},{&quot;first_name&quot;:&quot;Cameron&quot;,&quot;last_name&quot;:&quot;Stuver-Moody&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;Namchuk&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2011&quot;,&quot;month&quot;:&quot;10&quot;,&quot;day&quot;:&quot;04&quot;,&quot;issue&quot;:&quot;20&quot;,&quot;volume&quot;:&quot;54&quot;,&quot;pages&quot;:&quot;7184-7192&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm200712h&quot;},&quot;abstract&quot;:&quot;A high-throughput screen of our compound archive revealed a novel class of dual FMS-like tyrosine kinase 3 (FLT3)/c-KIT inhibitors. With the help of molecular modeling, this class was rapidly optimized for both potency against FLT3 and FLT3/c-KIT and excellent potency in cell-based assays, leading to dose-dependent cell death in acute myelogenous leukemia (AML) patient blast samples. Ultimately, the AML patient blast data defined the preferred target profile as we designed and evaluated a set of FLT3 selective and FLT3/c-KIT dual molecules. Further optimization for pharmacokinetic properties resulted in the selection of the dual FLT3/c-KIT inhibitor, N3-(4-(trans-4-morpholinocyclohexyl)phenyl)-1-(pyridin-2-yl)-1H-1,2,4-triazole-3,5-diamine, VX-322 (compound 37), to move forward to preclinical evaluation.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm200712h&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm200712h" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm200712h&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm200712h" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm200712h&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm200712h" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm200712h&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm200712h&amp;href=/doi/10.1021/jm200712h" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm200712h" /></input><a href="/doi/pdf/10.1021/jm200712h" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm200712h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm200712h%26sid%3Dliteratum%253Aachs%26pmid%3D21970471%26genre%3Darticle%26aulast%3DDavies%26date%3D2011%26atitle%3DDesign%252C%2BSynthesis%252C%2Band%2BEvaluation%2Bof%2Ba%2BNovel%2BDual%2BFms-Like%2BTyrosine%2BKinase%2B3%252FStem%2BCell%2BFactor%2BReceptor%2B%2528FLT3%252Fc-KIT%2529%2BInhibitor%2Bfor%2Bthe%2BTreatment%2Bof%2BAcute%2BMyelogenous%2BLeukemia%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D54%26issue%3D20%26spage%3D7184%26epage%3D7192%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/54/20" title="Go to Volume 54, Issue 20"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-20/jmcmar.2011.54.issue-20/production/jmcmar.2011.54.issue-20.largecover.jpg" alt="Go to Volume 54, Issue 20"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-20/jm200712h/production/images/medium/jm-2011-00712h_0006.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-20/jm200712h/production/images/large/jm-2011-00712h_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200712h&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">A high-throughput screen of our compound archive revealed a novel class of dual FMS-like tyrosine kinase 3 (FLT3)/c-KIT inhibitors. With the help of molecular modeling, this class was rapidly optimized for both potency against FLT3 and FLT3/c-KIT and excellent potency in cell-based assays, leading to dose-dependent cell death in acute myelogenous leukemia (AML) patient blast samples. Ultimately, the AML patient blast data defined the preferred target profile as we designed and evaluated a set of FLT3 selective and FLT3/c-KIT dual molecules. Further optimization for pharmacokinetic properties resulted in the selection of the dual FLT3/c-KIT inhibitor, <i>N</i><sup>3</sup>-(4-(<i>trans</i>-4-morpholinocyclohexyl)phenyl)-1-(pyridin-2-yl)-1<i>H</i>-1,2,4-triazole-3,5-diamine, VX-322 (compound <b>37</b>), to move forward to preclinical evaluation.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63264" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63264" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Acute myelogenous leukemia (AML) affects around 30,000 people annually worldwide and represents about 1.2% of cancers diagnosed in the United States.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> It is the most common adult leukemia and is very aggressive. Over 50% of AML patients are over the age of 60 and are often unable to withstand the high concentrations of cytotoxic agents, AraC and anthracyclines, which are the current standard of care.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> The remission rate for this age group is around 50%, and of those, only 10% achieve disease free survival for greater than 5 years.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3, 4)</a> This shows that there is a clear need for better therapeutic agents for this disease.</div><div class="NLM_p">AML occurs when normal hematopoietic stem cells are mutated into a state where they proliferate in an uncontrolled manner, without differentiating. This causes a dangerous overproduction of leukemic blasts (immature white blood cells) and underproduction of red blood cells and platelets.</div><div class="NLM_p">AML seems well suited for the therapeutic inhibition of the kinases involved in leukemic cell survival and proliferation. FMS-like tyrosine kinase 3 (FLT3) and stem cell factor receptor (c-KIT) are two closely related kinases that appear to be good candidates for this inhibition. They are both normally involved in the survival, proliferation, and differentiation of hematopoietic stem cells, but their expression and/or overactivation are common traits of AML blasts.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5, 6)</a></div><div class="NLM_p">In AML patient blasts, overexpression of wild-type c-KIT and FLT3 occurs, leading to growth stimulation upon binding of stem cell factor (SCF) or FLT3 ligand (FL).<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> In over half of these samples, the blasts were found to express both c-KIT and its ligand, SCF, such that the blasts have the potential to stimulate their own proliferation. This blast cell autostimulation also occurs frequently with FLT3 signaling, although through a different mechanism. In the case of FLT3, there are numerous mutations that lead to constitutive activation of the receptor in the absence of ligand. In AML, a number of activating mutations of FLT3 play a pathogenic role through an uncontrolled activation, which leads to a rapid proliferation of white blood cells, or blasts, which then interfere with the production of normal blood cells.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> The two major activating mutations are an internal tandem duplication (ITD)<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9, 10)</a> in the juxtamembrane region and a D835 mutation in the activation loop.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> These mutations are seen in 35% of AML cases and lead to a far worse prognosis for those patients.<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12, 13)</a></div><div class="NLM_p">AML treatment with small molecule FLT3 inhibitors has been a keen area of research over the past decade and has resulted in several potent compounds progressing to the clinic. Unfortunately, several candidates such as MLN-518 (tandutinib),<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> CEP-701 (lestaurtinib),<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> SU-11248 (sunitinib),<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> and BAY-43-9006 (sorafenib)<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> did not meet the desired end points<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18, 19)</a> for a variety of possible reasons, including poor pharmacokinetics, high serum-binding, or poor selectivity. However, PKC-412 (midostaurin)<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> is still under development for AML, in addition to one newer, improved FLT3 inhibitor, AC220, which is in midstage AML trials.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div><div class="NLM_p">The initial aim of our program was to identify potent FLT3 selective compounds, which could be evaluated in vitro and in vivo with the aim of providing a safer, more efficacious treatment for AML. As a first step toward developing such an inhibitor, our compound collection was screened against FLT3. Compound <b>1</b>, a 3,5-diamino-1,2,4-triazole, was one of the most promising hits from this screen, with an inhibition constant against FLT3 of 85 nM and no detectable inhibition of the other kinases tested.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-20/jm200712h/production/images/medium/jm-2011-00712h_0008.gif" alt="" id="fx1" /></img></div><div class="NLM_p">In addition to having a favorable inhibition profile, this hit class could also be readily modeled into the active site of our FLT3 homology model. The binding mode is depicted in Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>, with the diaminotriazole moiety making three hydrogen bonds to the hinge. A final advantage of this class was the availability of a facile synthetic route, which allowed for a rapid structure–activity relationship evaluation.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-20/jm200712h/production/images/medium/jm-2011-00712h_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-20/jm200712h/production/images/large/jm-2011-00712h_0009.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Compound <b>1</b> modeled into a FLT3 homology model. Hinge hydrogen bonds are shown as dashed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-20/jm200712h/production/images/large/jm-2011-00712h_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200712h&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83165" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83165" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The general synthetic route to the diaminotriazole analogues is depicted in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>. The triazole is synthesized in a regiospecific manner through the reaction of diphenyl cyanocarbonimidate (<b>2</b>) with stepwise displacements of the phenoxy group, first with an appropriately substituted aniline to give the imidate (<b>3</b>), followed by cyclization with an aryl hydrazine to give the triazole (<b>4</b>). In these cases, the reactions proceed to give predominantly, and in many cases exclusively, the 1,2,4-triazole as reported in the literature.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-20/jm200712h/production/images/medium/jm-2011-00712h_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-20/jm200712h/production/images/large/jm-2011-00712h_0010.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthetic Route to the 1,2,4-Triazoles<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-20/jm200712h/production/images/large/jm-2011-00712h_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200712h&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) ArNH<sub>2</sub>, <i>i</i>-PrOH or dioxane, reflux. (b) ArNHNH<sub>2</sub>, <i>i</i>-PrOH, or CH<sub>3</sub>CN or DMA, reflux, or microwave 180–220 °C.</p></p></figure><div class="NLM_p">Most of the substituted anilines were commercially available. Key anilines that did require synthesis included the 4-(4-morpholinocyclohexyl)anilines (<i>cis</i>- and <i>trans</i>-<b>8</b>, Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>). These were prepared through nitration of 4-phenylcyclohexanone (<b>5</b>) using nitronium tetrafluoroborate to give the 4-(4-nitrophenyl)cyclohexanone (<b>6</b>) in 43% yield. Reductive amination of the cyclohexanone <b>6</b> with morpholine gave both a mixture of the cis and trans isomers of 4-(4-(4-nitrophenyl)cyclohexyl)morpholine (<b>7</b>) in 90% yield, which were separated by flash chromatography with a 1:3 ratio of the cis:trans products, respectively. Both the <i>cis</i>-<b>7</b> and the <i>trans</i>-<b>7</b> nitro intermediates were reduced to their corresponding anilines (<i>cis</i>-<b>8</b> and <i>trans</i>-<b>8</b>). Following the above general procedure (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>), the triazoles <b>37</b> and <b>38</b> were obtained.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-20/jm200712h/production/images/medium/jm-2011-00712h_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-20/jm200712h/production/images/large/jm-2011-00712h_0011.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of 4-(4-Morpholinocyclohexyl)anilines<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-20/jm200712h/production/images/large/jm-2011-00712h_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200712h&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NO<sub>2</sub>BF<sub>4</sub>, CH<sub>3</sub>CN. (b) Morpholine, NaBH(OAc)<sub>3</sub>, THF. (c) Zn, NH<sub>4</sub>Cl, MeOH, reflux. (d) Compound <b>2</b>, iPrOH. (e) 2-Pyridylhydrazine, iPrOH, MW 180 °C.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61750" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61750" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">As a selective FLT3 inhibitor, compound <b>1</b> provided an excellent starting point for our lead optimization efforts. Compound <b>9</b> is included in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> as a second reference compound. Its activity is very similar to <b>1</b> but with a slight boost from the introduction of the additional methoxy group. Starting from these reference compounds, the first strategy pursued was to improve FLT3 potency by targeting lysine 644 with the intention of forming an additional hydrogen bond or salt bridge. The homology model in Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a> shows that this lysine should be easily reached from the para position of the hydrazine-derived phenyl. The nitrile and carboxyl of compounds <b>10</b> and <b>11</b> yielded significant potency enhancements, with inhibition constants of 22 and 24 nM, respectively. Compound <b>12</b> highlights the importance of the lysine interaction, as the 3-cyano substituent, unable to reach the lysine, leads to a moderate drop-off in potency. This is not to say that 3-substitutions are generally detrimental to activity. This site can access the glycine-rich loop, and hydrophobic groups such as the morpholine of <b>13</b> do yield potency improvements. At 11 nM, compound <b>13</b> approached the targeted potency levels but still fell short by approximately 10-fold. Another potency-enhancing strategy attempted was the stabilization of the flat, coplanar conformation of the triazole and the directly attached 1-phenyl.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-20/jm200712h/production/images/medium/jm-2011-00712h_0012.gif" alt="" id="fx2" /></img></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Effects of Planarity on FLT3 Affinity</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-20/jm200712h/production/images/medium/jm-2011-00712h_0013.gif" alt="" id="fx3" /></img><div></div></div><div class="NLM_p">The phenyl in compounds <b>1</b> and <b>9</b> is within the adenine-binding portion of the adenosine triphosphate (ATP) site, and compounds mimicking the flat, hydrophobic nature of adenine can be expected to improve potency. To evaluate the benefit of flatness and coplanarity, compounds <b>14</b>–<b>16</b> were synthesized, and their potency was assessed. As expected, the cyclohexyl and 2-chlorophenyl groups of <b>14</b> and <b>15</b> showed substantial loss in potency accompanying their less flat structures. The 2-fluoro of <b>16</b> does not have a significant effect relative to the unsubstituted phenyl. The 2-pyridyl analogue <b>17</b> was hypothesized to be the most planar and, therefore, most active, analogue. The internal hydrogen bond to the exocyclic 5-amine locks in the flat conformation without affecting other interactions to the protein, and upon synthesis, this compound had a 2.8 nM inhibition constant.</div><div class="NLM_p">Although compound <b>17</b> is sufficiently potent to determine its efficacy as a FLT3 inhibitor, selectivity remained an issue. Of 13 kinases routinely screened in-house, IRAK4 (43 nM), Janus kinase 2 (JAK2) (67 nM), and Aurora A (103 nM) were inhibited with <i>K</i><sub>i</sub> values at or under 100 nM, as was c-KIT (9 nM), another kinase involved in hematopoiesis. While we considered the possibility that dual FLT3/c-KIT inhibitors might convey some advantages over selective FLT3 inhibitors, our goal was for a generally selective compound. Because Cys 695 of FLT3 and c-KIT is a proline in Aurora A, JAK2, and IRAK4, it was hypothesized that steric bulk impinging on this residue would be less tolerated in those three kinases than in FLT3, leading to selectivity. To test the hypothesis, a set of analogues was synthesized with 2-substituents on the aniline ring, as shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-20/jm200712h/production/images/medium/jm-2011-00712h_0001.gif" alt="" id="fx4" /></img></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Selectivity Effects of Ar1 and Ar2</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-20/jm200712h/production/images/medium/jm-2011-00712h_0002.gif" alt="" id="fx5" /></img><div></div></div><div class="NLM_p">The data from these analogues largely confirms our hypothesis, with improved selectivity over Aurora A and JAK2, and modest improvements seen against IRAK4. Unexpectedly, compounds <b>23</b> and <b>24</b> also showed some degree of selectivity against c-KIT, which allowed us to assess the relative merits of FLT3 selective versus dual FLT3/c-KIT compounds.</div><div class="NLM_p">A set of FLT3 selective and dual FLT3/c-KIT inhibitors were tested for their ability to induce apoptosis in primary AML patient blast samples. The dual FLT3/c-KIT inhibitors were substantially and consistently more potent than FLT3 selective inhibitors.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> For this reason, the dual FLT3/c-KIT profile became our desired target compound profile and thus dictated our subsequent chemistry endeavors.</div><div class="NLM_p">In a separate exercise from the 2-substituted aniline analogues described above, a broader aniline substituent exploration was carried out with 2-pyridyl fixed at the 1-position of the triazole. The 3-position offers significant space underneath the flexible glycine-rich loop, while the 4-position sits at the edge of active site with vectors toward solvent. A representative subset of these compounds is shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>, where it can be seen that a broad range of substituents were tolerated at both positions. This tolerance in potency allowed an extensive search for a compound with optimal potency, selectivity, cell activity, and both physicochemical and pharmacokinetic properties for further preclinical testing. We explored multiple approaches to improve solubility, including a variety of linkers extending basic groups toward solvent. Although we saw improvements in physical properties in cases such as for N-linked compounds such as compound <b>26</b>, O-linked compounds such as compound <b>29</b> and C-linked compounds such as <b>34</b> and <b>35</b>, it was not until we extended with a cyclohexyl bridging group that we achieved all of the desired properties in one molecule.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Effects of Aniline Variation on in Vitro Kinase Binding, Kinase Selectivity, Cellular Activity, and Rat IV Pharmacokinetics</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-20/jm200712h/production/images/medium/jm-2011-00712h_0003.gif" alt="" id="fx6" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-20/jm200712h/production/images/medium/jm-2011-00712h_0004.gif" alt="" id="fx7" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">Selectivity is calculated as the geometric mean of the <i>K</i><sub>i</sub> values for 13 counterscreened kinases (JNK3, SRC, GSK3, CDK2, KDR, PKA, SYK, JAK2, IRAK4, ROCK1, MET, PLK1, and PI3 kg) divided by the FLT3 <i>K</i><sub>i</sub>.</p></div></div><div></div></div><div class="NLM_p">Compound <b>37</b> met our desired in vitro profile, providing the desired combination of FLT3/c-KIT enzyme potency, subtype selectivity, cellular potency, and good rat IV-PK. The molecule was advanced to multispecies oral PK, which is summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Oral PK of Compound <b>37</b> in Mouse, Rat, and Monkey</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center" char=".">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>(0–24 h)</sub>(h μg/mL)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> (μg/mL)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char=".">% <i>F</i></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse</td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="char" char=".">6.73</td><td class="colsep0 rowsep0" align="char" char=".">0.68</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">15.47</td><td class="colsep0 rowsep0" align="char" char=".">66</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="char" char=".">30</td><td class="colsep0 rowsep0" align="char" char=".">65.03</td><td class="colsep0 rowsep0" align="char" char=".">5.03</td><td class="colsep0 rowsep0" align="char" char=".">6</td><td class="colsep0 rowsep0" align="char" char=".">8.34</td><td class="colsep0 rowsep0" align="char" char=".">155</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">monkey</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">12.67</td><td class="colsep0 rowsep0" align="char" char=".">2.55</td><td class="colsep0 rowsep0" align="char" char=".">2.17</td><td class="colsep0 rowsep0" align="char" char=".">3.15</td><td class="colsep0 rowsep0" align="char" char=".">54</td></tr></tbody></table></div></div><div class="NLM_p">Compound <b>37</b> showed good oral bioavailability when dosed in 0.5% MC suspension in Balb/c mice, Sprague–Dawley rats, and cynomolgous monkeys. The bioavailability was 66 and 54% in mouse and monkey, respectively, and ranged in the rat between 43 and 155%, which was indicative of good absorption. The half-life following oral dose in rat (at 30 mg/kg) and monkey are similar to the half-life following intravenous dosing in rat and monkey, which is indicative that elimination is not limited by the absorption process at low dose. Importantly, compound <b>37</b> was cytotoxic in vitro at low nanomolar concentrations against AML patient isolates<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> harboring either wild type or mutant FLT3 (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Characterization of Compound <b>37</b> Across a Panel of Primary AML Patient Blast Cells</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">compd</th><th class="colsep0 rowsep0" align="center" char=".">96-2 (WT)</th><th class="colsep0 rowsep0" align="center" char=".">97-2 (D835Y)</th><th class="colsep0 rowsep0" align="center" char=".">2002-2 (ITD)</th><th class="colsep0 rowsep0" align="center" char=".">2003-3 (WT)</th><th class="colsep0 rowsep0" align="center" char=".">2003-5 (WT)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>37</b></td><td class="colsep0 rowsep0" align="char" char=".">0.1</td><td class="colsep0 rowsep0" align="char" char=".">0.22</td><td class="colsep0 rowsep0" align="char" char=".">0.012</td><td class="colsep0 rowsep0" align="char" char=".">0.02</td><td class="colsep0 rowsep0" align="char" char=".">0.025</td></tr></tbody></table></div></div><div class="NLM_p">In addition, compound <b>37</b> was equally active against AML cell lines expressing FLT3-ITD or c-KIT mutations but was not cytotoxic in the parental cell line (Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>).</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Cytotoxicity of Compound <b>37</b> against FLT3 and c-KIT Expressing Cell Lines</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char="."> </th><th class="rowsep1 colsep0" colspan="5" align="center" char=".">TF-1 RTK cell panel IC<sub>50</sub> (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">compd</th><th class="colsep0 rowsep0" align="center" char=".">FLT3-WT</th><th class="colsep0 rowsep0" align="center" char=".">FLT3-ITD</th><th class="colsep0 rowsep0" align="center" char=".">FLT3 D835Y</th><th class="colsep0 rowsep0" align="center" char=".">c-KIT</th><th class="colsep0 rowsep0" align="center" char=".">TF-1 parental</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>37</b></td><td class="colsep0 rowsep0" align="char" char=".">0.0005</td><td class="colsep0 rowsep0" align="char" char=".">0.0013</td><td class="colsep0 rowsep0" align="char" char=".">0.0014</td><td class="colsep0 rowsep0" align="char" char=".">0.0016</td><td class="colsep0 rowsep0" align="char" char=".">>4</td></tr></tbody></table></div></div><div class="NLM_p last">Compound <b>37</b> was also efficacious in a FLT3-ITD-dependent myeloproliferative mouse model, doubling survival as compared to other FLT3 inhibitors, with 25% of the mice cured.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Given these data, compound <b>37</b>, a potent dual FLT3/c-KIT inhibitor, was approved for preclinical evaluation.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42487" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42487" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">From an initial screening hit, the diaminotriazole scaffold was rapidly evolved to produce potent compounds, which could be modified to have either FLT3 selective or selective dual FLT3/c-KIT profiles. The latter dual profile was selected as this proved to be more potent and efficacious against primary AML patient blast cells.</div><div class="NLM_p">Compound <b>37</b> was deemed an ideal candidate, with excellent enzyme and cell potency for both FLT3 and c-KIT, as well as broad selectivity against other protein kinases. The molecule was cytotoxic against both FLT3 and c-KIT expressing cell lines with no effect on cells, which do not express these receptor tyrosine kinases (RTKs).<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-20/jm200712h/production/images/medium/jm-2011-00712h_0005.gif" alt="" id="fx8" /></img></div><div class="NLM_p last">The molecule also possessed excellent PK across three species, was potent in primary AML patient blast samples, and showed strong efficacy in a Ba/F3-FLT3-ITD leukemia mouse model. On the basis of these findings, compound <b>37</b> was selected to move forward toward preclinical evaluation.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81168" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81168" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">All commercially available reagents and anhydrous solvents were used without further purification. Purity assessment for final compounds based on analytical HPLC: column, 4.6 mm × 50 mm Waters YMC Pro-C18 column, 5 μm, 120A. Mobile phases are as follows: A, H<sub>2</sub>O with 0.2% formic acid; B, acetonitrile with 0.2% formic acid; gradient, 10–90% B in 3 min with 5 min run time. The flow rate is 1.5 mL/min. Unless specified otherwise, all compounds were ≥95% purity. Mass samples were analyzed on a Micro Mass ZQ, ZMD, Quattro LC, or Quatro II mass spectrometer operated in a single MS mode with electrospray ionization. Samples were introduced into the mass spectrometer using flow injection (FIA) or chromatography. The mobile phase for all mass analysis consisted of acetonitrile–water mixtures with either 0.2% formic acid or ammonium formate. The high-resolution mass spectrum was measured using a 9.4T APEX III FTMS Bruker Daltonics instrument. <sup>1</sup>H NMR spectra were recorded either using a Bruker DRX-500 (500 MHz) or a Bruker Avance II-300 (300 MHz) instrument. The column chromatography was performed using Merck silica gel 60 (0.040–0.063 mm). Preparative reversed phase chromatography was carried out using a Gilson 215 liquid handler coupled to a UV–vis 156 Gilson detector, an Agilent Zorbax SB-C18 column, 21.2 mm × 100 mm, a linear gradient from 10–90% CH<sub>3</sub>CN in H<sub>2</sub>O over 10 min (0.1% trifluoroacetic acid); the flow rate was 20 mL/min. Most of the anilines and the hydrazines were commercially available or synthesized following literature procedures.</div><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> 4-(4-Nitrophenyl)cyclohexanone (<b>6</b>)</h3><div class="NLM_p last">To a solution of 4-phenylcyclohexanone (4.36 g, 25 mmol) in dry acetonitrile (200 mL) cooled with an acetone–dry ice bath was added nitronium tetrafluoroborate (4.68 g, 35 mmol) in one portion under N<sub>2</sub>. After it was stirred for 15 min, the reaction mixture was stirred at 0 °C for 2 h, treated with ice chips, and evaporated. The residue was suspended in water and extracted with ethyl acetate (EtOAc) (3×), and the organic phase was washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and evaporated. The residue was purified by flash chromatography (SiO<sub>2</sub>) eluted with EtOAc/hexanes (15:85) to give 4-(2-nitrophenyl)cyclohexanone (475 mg, yellow solid, 8.6% yield) and then the desired product 4-(4-nitrophenyl)cyclohexanone <b>6</b> (2.36 g, yellow solid, 43% yield). FIA-MS: 220.1 [M + 1]. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.12 (dt, <i>J</i> = 8.7, 2.2, 2H), 7.34 (dt, <i>J</i> = 8.7, 2.2, 2H), 3.08 (tt, <i>J</i> = 12.2, 3.4 Hz, 1H), 2.51–2.43 (m, 4H), 2.18 (ddd, <i>J</i> = 10.5, 5.8, 3.2 Hz, 2H), 1.97–1.83 (m, 2H).</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> 4-(<i>cis</i>-4-(4-Nitrophenyl)cyclohexyl)morpholine (<i>cis</i>-<b>7</b>) and 4-(<i>trans</i>-4-(4-Nitrophenyl)cyclohexyl)morpholine (<i>trans</i>-<b>7</b>)</h3><div class="NLM_p last">A suspension of 4-(4-nitrophenyl)cyclohexanone <b>6</b> (493 mg, 2.28 mmol), morpholine (0.2 mL, 2.28 mmol), and sodium triacetoxyborohydride (678 mg, 3.2 mmol) in THF (15 mL) was stirred for 24 h. Thin-layer chromatography (TLC) indicated that the reaction was incomplete. Additional sodium triacetoxyborohydride (151 mg) was added. The reaction mixture was stirred for another 24 h, treated with saturated sodium bicarbonate, and extracted with EtOAc (3×). The combined organic phases were washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. The crude was purified by flash chromatography (SiO<sub>2</sub>) eluted with dichloromethane (CH<sub>2</sub>Cl<sub>2</sub>)/methanol (MeOH)/28% ammonium hydroxide (NH<sub>4</sub>OH) (98:2:0.2) to give <i>cis</i><b>-7</b> as a yellow oil (428 mg, 65% yield) and <i>trans</i><b>-7</b> as a yellow solid (150 mg, 23%). Data for <i>cis</i><b>-7</b>: FIA-MA: 291.1 [M + 1]. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.16 (d, <i>J</i> = 8.9 Hz, 2H), 7.52 (d, <i>J</i> = 8.8 Hz, 2H), 3.62 (t, <i>J</i> = 4.6 Hz, 4H), 2.82 (tt, <i>J</i> = 10.9, 3.7 Hz, 1H), 2.39 (br.s, 4H), 2.18 (s, 1H), 2.02–1.89 (m, 2H), 1.82 (dt, <i>J</i> = 13.1, 11.1 Hz, 2H), 1.59–1.47 (m, 4H). Data for <i>trans</i><b>-7</b>: FIA-MS: 291.1 [M + 1]. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.14 (d, <i>J</i> = 8.7 Hz, 2H), 7.52 (d, <i>J</i> = 8.7 Hz, 2H), 3.60–3.54 (m, 4H), 2.63 (tt, <i>J</i> = 11.9, 3.3 Hz, 1H), 2.6 (m, 4H), 2.30 (m, 1H), 1.93 (d, <i>J</i> = 11.5 Hz, 2H), 1.88 (d, <i>J</i> = 11.9 Hz, 2H), 1.51 (q, <i>J</i> = 13.6 Hz, 2H), 1.36 (q, <i>J</i> = 12.6 Hz, 2H).</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> 4-(<i>trans</i>-4-Morpholinocyclohexyl)aniline (<i>trans</i>-<b>8</b>) and <i>N</i><sup>3</sup>-(4-(<i>trans</i>-4-Morpholinocyclohexyl)phenyl)-1-(pyridin-2-yl)-1<i>H</i>-1,2,4-triazole-3,5-diamine (<b>37</b>)</h3><div class="NLM_p">To a solution of 4-(<i>trans</i>-4-(4-nitrophenyl)cyclohexyl)morpholine (150 mg, 0.52 mmol) in MeOH (15 mL) were added zinc dust (169 mg, 2.58 mmol) and ammonium chloride (110 mg, 2.0 mmol). The resulting suspension was heated under reflux for 1 h, cooled to room temperature, filtered through Celite, and washed with MeOH. The filtrate was evaporated to give crude 4-(<i>trans</i>-4-morpholinocyclohexyl)aniline (<i>trans</i>-<b>8</b>). LC-MS: 261.1 [M + 1]. Without further purification, the aniline was dissolved in isopropanol (20 mL) and stirred with diphenyl cyanocarbonimidate (129 mg, 0.54 mmol) for 5 days under N<sub>2</sub>. The solvent was removed in vacuo, and the residue was purified by flash chromatography (SiO<sub>2</sub>) (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/28% NH<sub>4</sub>OH 96:4:0.4) to give phenyl <i>N</i>′-cyano-<i>N</i>-(4-(<i>trans</i>-4-morpholinocyclohexyl)phenyl)carbamimidate as an off-white solid (113 mg, 57% yield). FIA-MS: 405.1 [M + 1], 403.2 [M – 1]. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.6 (s, 1H, NH), 7.44 (t, <i>J</i> = 7.8 Hz, 2H), 7.35 (d, <i>J</i> = 8.3 Hz, 2H), 7.32–7.21 (m, 5H), 3.57 (m, 4H), 2.47 (m, 1H), 2.7–2.5 (m, 5H), 2.31–2.23 (m, 1H), 1.92 (d, <i>J</i> = 10.0 Hz, 2H), 1.84 (d, <i>J</i> = 11.7 Hz, 2H), 1.45 (q, <i>J</i> = 13.7 Hz, 2H), 1.33 (q, <i>J</i> = 13.7 Hz, 2H).</div><div class="NLM_p last">A mixture of phenyl <i>N</i>′-cyano-<i>N</i>-(4-(<i>trans</i>-4-morpholinocyclohexyl)phenyl)carbamimidate (113 mg, 0.28 mmol) and 2-pyridylhydrazine (32 mg, 0.29 mmol) in isopropanol (3 mL) was heated in a microwave oven at 180 °C for 10 min. After the mixture was cooled, the precipitate was collected and washed with isopropanol to give 61 mg of <i>N</i><sup>3</sup>-(4-(<i>trans</i>-4-morpholinocyclohexyl)phenyl)-1-(pyridin-2-yl)-1<i>H</i>-1,2,4-triazole-3,5-diamine (<b>37</b>). The product was further purified by reverse phase HPLC (C-18, water/CH<sub>3</sub>CN). LC-MS: 420.1 [M + 1]. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.59 (br. s, 1H), 8.99 (s, 1H), 8.41 (d, <i>J</i> = 4.4 Hz, 1H), 7.97 (t, <i>J</i> = 7.8 Hz, 1H), 7.68 (d, <i>J</i> = 8.3 Hz, 1H), 7.65 (br. s, 1H), 7.54 (d, <i>J</i> = 8.5 Hz, 2H), 7.21 (dd, <i>J</i> = 7.2, 5.5, 1H), 7.11 (d, <i>J</i> = 8.4 Hz, 2H), 4.02 (d, <i>J</i> = 11.3 Hz, 2H), 3.70 (t, <i>J</i> = 11.9 Hz, 2H), 3.44 (d, <i>J</i> = 11.8 Hz, 2H), 3.28 (m, 1H), 3.20–3.09 (m, 2H), 2.45 (t, <i>J</i> = 11.6 Hz, 1H), 2.18 (d, <i>J</i> = 11.8 Hz, 2H), 1.96 (d, <i>J</i> = 12.5 Hz, 2H), 1.58 (q, <i>J</i> = 11.7 Hz, 2H), 1.49 (q, <i>J</i> = 12.7 Hz, 2H).</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> 4-(<i>cis</i>-4-Morpholinocyclohexyl)aniline (<i>cis</i>-<b>5</b>′) and <i>N</i><sup>3</sup>-(4-(<i>cis</i>-4-Morpholinocyclohexyl)phenyl)-1-(pyridin-2-yl)-1<i>H</i>-1,2,4-triazole-3,5-diamine (<b>38</b>)</h3><div class="NLM_p">As described for <i>trans</i>-<b>8</b>, with 4-(<i>cis</i>-4-(4-nitrophenyl)cyclohexyl)morpholine (428 mg, 1.47 mmol), zinc dust (482 mg, 7.37 mmol) and ammonium chloride (316 mg, 5.90 mmol) in MeOH (15 mL) gave <i>cis</i>-<b>5</b>′. After treatment with diphenyl cyanocarbonimidate (369 mg, 1.55 mmol) in isopropanol (20 mL), phenyl <i>N</i>′-cyano-<i>N</i>-(4-(<i>cis</i>-4-morpholinocyclohexyl)phenyl)carbamimidate was obtained as a yellow solid (328 mg, 55% yield). LC-MS: 404.2 [M + 1]. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.7 (s, 1H), 7.44 (t, <i>J</i> = 7.9 Hz, 2H), 7.37 (d, <i>J</i> = 8.5 Hz, 2H), 7.33–7.22 (m, 5H), 3.61 (m, 4H), 2.67–2.61 (m, 1H), 2.39 (br. s, 4H), 2.17 (br. s, 1H), 1.96–1.90 (m, 2H), 1.86–1.69 (m, 2H), 1.55–1.42 (m, 4H).</div><div class="NLM_p last">As described for <b>37</b>, with phenyl <i>N</i>′-cyano-<i>N</i>-(4-(<i>cis</i>-4-morpholinocyclohexyl) phenyl)carbamimidate (328 mg, 0.81 mmol), 2-pyridylhydrazine (92 mg, 0.85 mmol) in isopropanol (3 mL) to give 134 mg of <b>38</b> after reverse phase HPLC purification. LC-MS: 420.1 [M + 1]. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.21 (br. s, 1H), 9.01 (s, 1H), 8.41 (d, <i>J</i> = 3.2 Hz, 1H), 7.98 (td, <i>J</i> = 7.85, 1.86, 1H), 7.68 (d, <i>J</i> = 8.4 Hz, 1H), 7.65 (s, 1H), 7.59 (d, <i>J</i> = 8.6 Hz, 2H), 7.23 (d, <i>J</i> = 8.6 Hz, 2H), 7.22–7.17 (m, 1H), 3.97 (d, <i>J</i> = 10.9 Hz, 2H), 3.68 (t, <i>J</i> = 11.8 Hz, 2H), 3.49 (d, <i>J</i> = 12.2 Hz, 2H), 3.32 (br. s, 1H), 3.04 (q, <i>J</i> = 11.3 Hz, 2H), 2.85 (br. s, 1H), 2.18–2.06 (m, 2H), 1.92–1.85 (m, 2H), 1.79–1.70 (m, 4H).</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Biochemical Kinase Assays</h3><div class="NLM_p last">The kinase activity against FLT3 or c-KIT was determined by radiometric assays using a recombinant human FLT3 or c-KIT kinase domain. The assay was carried out in 96-well plates containing 100 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (HEPES) (pH 7.5), 10 mM MgCl<sub>2</sub>, 25 mM NaCl, 0.01% bovine serum albumin (BSA), 1 mM dithiothreitol (DTT), 0.5 mg/mL polyE4Y, with 1.5 nM FLT3 or 5 nM c-KIT, and <sup>33</sup>P ATP at 90 and 700 μM, respectively. Inhibitors were dissolved in DMSO, and the reaction was initiated by the addition of <sup>33</sup>P ATP and polyE4Y. After 20 min, the reaction was quenched with 50 μL of 20% TCA containing 4 mM ATP. The reaction mix was transferred to GF/B filter plates and washed three times with 5% TCA. Following the addition of 50 μL of Ultimate Gold<sup></sup> scintillant, the samples were counted in a Packard TopCount. The <i>K</i><sub>i</sub> value was determined by fitting the data to the kinetic model for competitive tight binding inhibition. Kinase selectivity assays were performed either at Vertex using a spectrophotometric readout or were performed at Millipore (Billerica, MA) using their KinaseProfiler protocols.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Molecular Modeling</h3><div class="NLM_p last">Almost all molecular modeling was performed with a homology model of FLT3 based on the original crystal structure of Vascular Endothelial Growth Factor Receptor 2 (KDR; PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1VR2">1VR2</a>).<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Late in the course of this work, the FLT3 crystal structure became available (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1RJB">1RJB</a>) for use in modeling.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> In using the FLT3 structure for modeling, the JM-B domain of the juxtamembrane domain was removed from the active site to accommodate ligand binding. The KDR-based homology was generated with the MOE software package, and all ligands were built and evaluated in MOE using the MMFF94x force field.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20"><a href="/doi/suppl/10.1021/jm200712h">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00150" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00150" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last"><sup>1</sup>H NMR and MS spectral data for all of the final compounds. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm200712h/suppl_file/jm200712h_si_001.pdf">jm200712h_si_001.pdf (124.17 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm200712h" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86648" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86648" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert J. Davies</span> - <span class="hlFld-Affiliation affiliation">Vertex Pharmaceuticals Inc., 130 Waverly Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#56243934332422093237203f3325162024222e7835393b"><span class="__cf_email__" data-cfemail="d4a6bbb6b1a6a08bb0b5a2bdb1a794a2a6a0acfab7bbb9">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Albert C. Pierce</span> - <span class="hlFld-Affiliation affiliation">Vertex Pharmaceuticals Inc., 130 Waverly Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cornelia Forster</span> - <span class="hlFld-Affiliation affiliation">Novartis IBMR, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ron Grey</span> - <span class="hlFld-Affiliation affiliation">Vertex Pharmaceuticals Inc., 130 Waverly Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jinwang Xu</span> - <span class="hlFld-Affiliation affiliation">Vertex Pharmaceuticals Inc., 130 Waverly Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Arnost</span> - <span class="hlFld-Affiliation affiliation">Vertex Pharmaceuticals Inc., 130 Waverly Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Deborah Choquette</span> - <span class="hlFld-Affiliation affiliation">Amgen, 1 Kendall Square, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vincent Galullo</span> - <span class="hlFld-Affiliation affiliation">Astra Zeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shi-Kai Tian</span> - <span class="hlFld-Affiliation affiliation">University of Science & Technology of China, Hefei, Anhui 230026, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Greg Henkel</span> - <span class="hlFld-Affiliation affiliation">Arisan Therapeutics, 21512 Canaria, Mission Viejo, California 92692, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Guanjing Chen</span> - <span class="hlFld-Affiliation affiliation">Novartis IBMR, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David K. Heidary</span> - <span class="hlFld-Affiliation affiliation">University of Kentucky, Lexington, Kentucky 40506, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joanne Ma</span> - <span class="hlFld-Affiliation affiliation">Merck West Point, 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cameron Stuver-Moody</span> - <span class="hlFld-Affiliation affiliation">Vertex Pharmaceuticals Inc., 130 Waverly Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark Namchuk</span> - <span class="hlFld-Affiliation affiliation">Vertex Pharmaceuticals Inc., 130 Waverly Street, Cambridge, Massachusetts 02139, United States</span></div></li></ul></li><li></li><li></li><li></li></ul></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i21" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i21"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i22" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i22"> Abbreviations Used</h2><tr><td class="NLM_term">FLT3</td><td class="NLM_def"><p class="first last">FMS-like tyrosine kinase 3</p></td></tr><tr><td class="NLM_term">AML</td><td class="NLM_def"><p class="first last">acute myelogenous leukemia</p></td></tr><tr><td class="NLM_term">RTK</td><td class="NLM_def"><p class="first last">receptor tyrosine kinase</p></td></tr><tr><td class="NLM_term">ITD</td><td class="NLM_def"><p class="first last">internal tandem duplication</p></td></tr><tr><td class="NLM_term">JAK2</td><td class="NLM_def"><p class="first last">Janus kinase 2</p></td></tr><tr><td class="NLM_term">TLC</td><td class="NLM_def"><p class="first last">thin-layer chromatography</p></td></tr><tr><td class="NLM_term">MeOH</td><td class="NLM_def"><p class="first last">methanol</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">CH<sub>2</sub>Cl<sub>2</sub></td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">NH<sub>4</sub>OH</td><td class="NLM_def"><p class="first last">ammonium hydroxide</p></td></tr><tr><td class="NLM_term">HEPES</td><td class="NLM_def"><p class="first last">4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid)</p></td></tr><tr><td class="NLM_term">DTT</td><td class="NLM_def"><p class="first last">dithiothreitol</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">BSA</td><td class="NLM_def"><p class="first last">bovine serum albumin</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83515" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83515" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 28 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Groves, F. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linet, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devesa, S. S.</span><span> </span><span class="NLM_article-title">Patterns of occurrence of the leukemias</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">31A</span><span class="NLM_x">, </span> <span class="NLM_fpage">941</span><span class="NLM_x">–</span> <span class="NLM_lpage">949</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31A&publication_year=1995&pages=941-949&author=F.+D.+Grovesauthor=M.+S.+Linetauthor=S.+S.+Devesa&title=Patterns+of+occurrence+of+the+leukemias"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGroves%26aufirst%3DF.%2BD.%26aulast%3DLinet%26aufirst%3DM.%2BS.%26aulast%3DDevesa%26aufirst%3DS.%2BS.%26atitle%3DPatterns%2520of%2520occurrence%2520of%2520the%2520leukemias%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D1995%26volume%3D31A%26spage%3D941%26epage%3D949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Appelbaum, F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gundacker, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Head, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slovak, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willman, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godwin, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petersdorf, S. H.</span><span> </span><span class="NLM_article-title">Age and acute myeloid leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">3481</span><span class="NLM_x">–</span> <span class="NLM_lpage">3485</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2006&pages=3481-3485&author=F.+R.+Appelbaumauthor=H.+Gundackerauthor=D.+R.+Headauthor=M.+L.+Slovakauthor=C.+L.+Willmanauthor=J.+E.+Godwinauthor=J.+E.+Andersonauthor=S.+H.+Petersdorf&title=Age+and+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAppelbaum%26aufirst%3DF.%2BR.%26aulast%3DGundacker%26aufirst%3DH.%26aulast%3DHead%26aufirst%3DD.%2BR.%26aulast%3DSlovak%26aufirst%3DM.%2BL.%26aulast%3DWillman%26aufirst%3DC.%2BL.%26aulast%3DGodwin%26aufirst%3DJ.%2BE.%26aulast%3DAnderson%26aufirst%3DJ.%2BE.%26aulast%3DPetersdorf%26aufirst%3DS.%2BH.%26atitle%3DAge%2520and%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2006%26volume%3D107%26spage%3D3481%26epage%3D3485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Brien, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faderl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jabbour, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Manero, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wierda, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierce, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estey, E.</span><span> </span><span class="NLM_article-title">Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: Predictive prognostic models for outcome</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">1090</span><span class="NLM_x">–</span> <span class="NLM_lpage">1098</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2006&pages=1090-1098&author=H.+Kantarjianauthor=S.+O%27Brienauthor=J.+Cortesauthor=F.+Gilesauthor=S.+Faderlauthor=E.+Jabbourauthor=G.+Garcia-Maneroauthor=W.+Wierdaauthor=S.+Pierceauthor=J.+Shanauthor=E.+Estey&title=Results+of+intensive+chemotherapy+in+998+patients+age+65+years+or+older+with+acute+myeloid+leukemia+or+high-risk+myelodysplastic+syndrome%3A+Predictive+prognostic+models+for+outcome"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DO%2527Brien%26aufirst%3DS.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DGiles%26aufirst%3DF.%26aulast%3DFaderl%26aufirst%3DS.%26aulast%3DJabbour%26aufirst%3DE.%26aulast%3DGarcia-Manero%26aufirst%3DG.%26aulast%3DWierda%26aufirst%3DW.%26aulast%3DPierce%26aufirst%3DS.%26aulast%3DShan%26aufirst%3DJ.%26aulast%3DEstey%26aufirst%3DE.%26atitle%3DResults%2520of%2520intensive%2520chemotherapy%2520in%2520998%2520patients%2520age%252065%2520years%2520or%2520older%2520with%2520acute%2520myeloid%2520leukemia%2520or%2520high-risk%2520myelodysplastic%2520syndrome%253A%2520Predictive%2520prognostic%2520models%2520for%2520outcome%26jtitle%3DCancer%26date%3D2006%26volume%3D106%26spage%3D1090%26epage%3D1098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Tallman, M. S.</span><span> </span><span class="NLM_article-title">New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents</span> <span class="citation_source-journal">Hematol. Am. Soc. Hematol. Educ. Program</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_fpage">143</span><span class="NLM_x">–</span> <span class="NLM_lpage">150</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm200712h&amp;key=10.1182%2Fasheducation-2005.1.143" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm200712h&amp;key=16304372" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm200712h&amp;key=1%3ACAS%3A280%3ADC%252BD2Mnit1Cgtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&pages=143-150&author=M.+S.+Tallman&title=New+strategies+for+the+treatment+of+acute+myeloid+leukemia+including+antibodies+and+other+novel+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents</span></div><div class="casAuthors">Tallman Martin S</div><div class="citationInfo"><span class="NLM_cas:title">Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">143-50</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The prognosis for younger adults (< or = 55-60 years) with acute myeloid leukemia (AML) has improved during the last four decades.  However, there has been little progress in the treatment of older adults.  This disappointing observation is important because the median age of patients with AML is about 70 years.  Approximately 60%-80% of younger adults with AML achieve complete remission (CR) with the cytotoxic agents cytarabine and an anthracycline such as daunorubicin or idarubicin or the anthracenedione mitoxantrone.  However, only 30%-40% of such patients are alive and disease-free at 5 years.  Among older adults, CR is achieved in 40%-55%, but there are very few long-term survivors.  Many studies have evaluated the impact of alternative doses and schedules, as well as additional cytotoxic drugs, on the prognosis for this group of patients.  The outcome has not improved substantially beyond that achieved with conventional doses of an anthracycline and cytarabine followed by high-dose cytarabine consolidation.Several factors identified at diagnosis can predict outcome.  The most important of these is the karyotype of the leukemic cells.  Another critical factor is the presence of transmembrane transporter proteins, which confer multidrug resistance and mutations in or overexpression of specific genes such as WT1, C/EBPalpha, BAX, and BCL-2/BAX ratio, BAALC, EVI1, KIT and FLT3.  The development of specific agents directed at gene mutations, signal transduction pathways and unique cell surface antigens provide the foundation for new therapeutic strategies.  Such agents include the immunoconjugate gemtuzumab ozogamicin, multidrug resistance inhibitors, farnesyltransferase inhibitors, histone deacetylase and proteosome inhibitors, antiangiogenesis agents, FLT3 inhibitors, apoptosis inhibitors, and nucleoside analogs.  All of these agents can potentially address the heterogeneous abnormalities in AML and significantly improve the outcome for patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS47oWJXey1eYkFb3mqPUYDfW6udTcc2ebHhlfVfSIrZ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2Mnit1Cgtw%253D%253D&md5=7699fd99a00cfe70522bcbf5200e957d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1182%2Fasheducation-2005.1.143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fasheducation-2005.1.143%26sid%3Dliteratum%253Aachs%26aulast%3DTallman%26aufirst%3DM.%2BS.%26atitle%3DNew%2520strategies%2520for%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%2520including%2520antibodies%2520and%2520other%2520novel%2520agents%26jtitle%3DHematol.%2520Am.%2520Soc.%2520Hematol.%2520Educ.%2520Program%26date%3D2005%26spage%3D143%26epage%3D150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Kell, J.</span><span> </span><span class="NLM_article-title">Emerging treatments in acute myeloid leukaemia</span> <span class="citation_source-journal">Expert Opin. Emerging Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">55</span><span class="NLM_x">–</span> <span class="NLM_lpage">71</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm200712h&amp;key=10.1517%2F14728214.9.1.55" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm200712h&amp;key=15155136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm200712h&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkt1Ggt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=55-71&author=J.+Kell&title=Emerging+treatments+in+acute+myeloid+leukaemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging treatments in acute myeloid leukaemia</span></div><div class="casAuthors">Kell, Jonathan</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Emerging Drugs</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">55-71</span>CODEN:
                <span class="NLM_cas:coden">EOEDA3</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Acute myeloid leukemia (AML) is the most common form of leukemia in young adults.  Although 75-85% of patients will achieve complete remission after induction chemotherapy, the long-term survival is still < 50% at 5 yr.  Chemotherapy has increased in intensity in recent years and is perceived to have reached the limit of toxicity.  Allogeneic bone marrow transplantation, which is undoubtedly the most effective way to prevent relapse, may not add substantial survival benefits.  Several new pharmacol. approaches to the treatment of AML are now becoming available, with various mol. targets identified, including the farnesylation of RAS family proteins and tyrosine kinases involved in signal transduction and epigenetic methylation.  More selective delivery of chemotherapeutic agents is also feasible using humanized monoclonal antibodies, with the intriguing possibility of increasing treatment delivery without increasing the toxicity.  However, despite the progress in the rational design of drugs in disorders such as chronic myeloid leukemia, AML lacks a single specific pathognomic genetic event to act as a drug target.  This review discusses the drugs presently under investigation in Phase II or Phase III trials in AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXX3SUG1IFfbVg90H21EOLACvtfcHk0lika3XngrMKjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkt1Ggt7o%253D&md5=f5a92e0293b91905556ee34bafe486b9</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1517%2F14728214.9.1.55&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728214.9.1.55%26sid%3Dliteratum%253Aachs%26aulast%3DKell%26aufirst%3DJ.%26atitle%3DEmerging%2520treatments%2520in%2520acute%2520myeloid%2520leukaemia%26jtitle%3DExpert%2520Opin.%2520Emerging%2520Drugs%26date%3D2004%26volume%3D9%26spage%3D55%26epage%3D71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Banerji, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sattler, M.</span><span> </span><span class="NLM_article-title">Targeting mutated tyrosine kinases in the therapy of myeloid leukaemias</span> <span class="citation_source-journal">Expert Opin. Ther. Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">221</span><span class="NLM_x">–</span> <span class="NLM_lpage">239</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm200712h&amp;key=10.1517%2F14728222.8.3.221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm200712h&amp;key=15161429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm200712h&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkt1Ghu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2004&pages=221-239&author=L.+Banerjiauthor=M.+Sattler&title=Targeting+mutated+tyrosine+kinases+in+the+therapy+of+myeloid+leukaemias"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting mutated tyrosine kinases in the therapy of myeloid leukaemias</span></div><div class="casAuthors">Banerji, Lolita; Sattler, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">221-239</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Myeloid leukemias are frequently assocd. with translocations and mutations of tyrosine kinase genes.  The products of these oncogenes, including BCR-ABL, TEL-PDGFR, Flt3 and c-Kit, have elevated tyrosine kinase activity and transform hematopoietic cells, mainly by augmentation of proliferation and enhanced viability.  Activated ABL kinases are assocd. with chronic myeloid leukemia.  Mutations in platelet-derived growth factor receptor β are assocd. with chronic myelomonocytic leukemia.  Flt3 or c-Kit cooperate with other types of oncogenes to create fully transformed acute leukemias.  Elevated activity of these tyrosine kinases is crucial for transformation, thus making the kinase domain an ideal target for therapeutic intervention.  Tyrosine kinase inhibitors for various kinases are currently being evaluated in clin. trials and are potentially useful therapeutic agents in myeloid leukemias.  Here, the authors review the signaling activities, mechanism of transformation and therapeutic targeting of several tyrosine kinase oncogenes important in myeloid leukemias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkIyhaSO7b1bVg90H21EOLACvtfcHk0lika3XngrMKjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkt1Ghu70%253D&md5=f96061c0ac5c290bc5a0cd2b983807b7</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1517%2F14728222.8.3.221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.8.3.221%26sid%3Dliteratum%253Aachs%26aulast%3DBanerji%26aufirst%3DL.%26aulast%3DSattler%26aufirst%3DM.%26atitle%3DTargeting%2520mutated%2520tyrosine%2520kinases%2520in%2520the%2520therapy%2520of%2520myeloid%2520leukaemias%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2004%26volume%3D8%26spage%3D221%26epage%3D239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Stacchini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fubini, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Severino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanavio, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aglietta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piacibello, W.</span><span> </span><span class="NLM_article-title">Expression of type III receptor tyrosine kinases FLT3 and KIT and responses to their ligands by acute myeloid leukemia blasts</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">1584</span><span class="NLM_x">–</span> <span class="NLM_lpage">1591</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm200712h&amp;key=8847893" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm200712h&amp;key=1%3ACAS%3A280%3ADyaK28vgsVeltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1996&pages=1584-1591&issue=10&author=A.+Stacchiniauthor=L.+Fubiniauthor=A.+Severinoauthor=F.+Sanavioauthor=M.+Agliettaauthor=W.+Piacibello&title=Expression+of+type+III+receptor+tyrosine+kinases+FLT3+and+KIT+and+responses+to+their+ligands+by+acute+myeloid+leukemia+blasts"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of type III receptor tyrosine kinases FLT3 and KIT and responses to their ligands by acute myeloid leukemia blasts</span></div><div class="casAuthors">Stacchini A; Fubini L; Severino A; Sanavio F; Aglietta M; Piacibello W</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1584-91</span>
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    </div><div class="casAbstract">The stem cell tyrosine kinase 1 (STK1) protein is the human homologue of the murine FLT3 gene product, a receptor belonging to the FMS/KIT family.  FLT3 and KIT with their ligands control the growth and differentiation of early human hemopoietic cells.  In the present study, 16 cases of acute myeloid leukemia (AML) were examined by flow cytometry for cell surface expression of FLT3 and KIT receptors.  All cases were also tested for their proliferative response to human FLT3 ligand (FL) and KIT ligand (KL) and for colony formation in the presence of single or associated cytokines.  Among 16 AML cases tested, 10/16 expressed FLT3 receptor and 12/16 expressed KIT receptor, without any correlation with FAB subtype.  FL and KL stimulated the proliferation of leukemic blasts in 11/16 AML cases (including five FLT3 or KIT receptor-negative cases), with an additive effect when added simultaneously.  By contrast, some receptor-expressing AMLs did not display significant proliferative responses to their respective ligands.  FL and KL as single factors induced or significantly increased the colony formation by clonogenic precursor cells respectively in eight and six of 13 cases tested.  In some cases growth factor association significantly enhanced colony growth.  Taken together these observations provide evidence that the pattern of FLT3 and KIT receptor expression is extremely variable among the AMLs and that receptor presence is not necessarily combined with proliferative and clonogenic response or vice versa.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTHFEG53WGqAIJKJbLTgsvCfW6udTcc2eaGdj7-EPq2Rbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK28vgsVeltw%253D%253D&md5=ec4bb7977b25849a6eaec661d94d23eb</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStacchini%26aufirst%3DA.%26aulast%3DFubini%26aufirst%3DL.%26aulast%3DSeverino%26aufirst%3DA.%26aulast%3DSanavio%26aufirst%3DF.%26aulast%3DAglietta%26aufirst%3DM.%26aulast%3DPiacibello%26aufirst%3DW.%26atitle%3DExpression%2520of%2520type%2520III%2520receptor%2520tyrosine%2520kinases%2520FLT3%2520and%2520KIT%2520and%2520responses%2520to%2520their%2520ligands%2520by%2520acute%2520myeloid%2520leukemia%2520blasts%26jtitle%3DLeukemia%26date%3D1996%26volume%3D10%26issue%3D10%26spage%3D1584%26epage%3D1591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Kiyoi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoe, T.</span><span> </span><span class="NLM_article-title">FLT3 mutations in acute myeloid leukemia</span> <span class="citation_source-journal">Methods Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">125</span><span class="NLM_x">, </span> <span class="NLM_fpage">189</span><span class="NLM_x">–</span> <span class="NLM_lpage">197</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm200712h&amp;key=16502586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm200712h&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFyqtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2006&pages=189-197&author=H.+Kiyoiauthor=T.+Naoe&title=FLT3+mutations+in+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 mutations in acute myeloid leukemia</span></div><div class="casAuthors">Kiyoi, Hitoshi; Naoe, Tomoki</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">Myeloid Leukemia</span>),
    <span class="NLM_cas:pages">189-197</span>CODEN:
                <span class="NLM_cas:coden">MMMEFN</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">A review.  The prevalence of an internal tandem duplication (ITD) of the juxtamembrane domain-coding sequence and a missense mutation of D835 within the kinase domain of the FLT3 gene is 15-35% and 5-10% of adults with acute myeloid leukemia (AML), resp.  In addn., point mutations, deletions, and insertions have been found in the juxtamembrane domain and in the other codons within the kinase domain, though these are less common.  Several large-scale studies in well-documented patients published to date have demonstrated that FLT3 mutations are strongly assocd. with a poor prognosis and a high leukemia cell count in patients with AML, suggesting that FLT3 mutations are involved in disease progression.  Because the detection of FLT3 mutations is fast, easy, and inexpensive, mutation anal. should be performed as a routine test.  This chapter describes methods for detecting ITD and D835 mutations in the FLT3 gene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYmCy3nijk3bVg90H21EOLACvtfcHk0lika3XngrMKjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFyqtb8%253D&md5=21b20ab38e23dcbf607640e787e07a35</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKiyoi%26aufirst%3DH.%26aulast%3DNaoe%26aufirst%3DT.%26atitle%3DFLT3%2520mutations%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DMethods%2520Mol.%2520Med.%26date%3D2006%26volume%3D125%26spage%3D189%26epage%3D197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Nakao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokota, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaneko, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horiike, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kashima, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sonoda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujimoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Misawa, S.</span><span> </span><span class="NLM_article-title">Internal tandem duplication of the flt3 gene found in acute myeloid leukemia</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">1911</span><span class="NLM_x">–</span> <span class="NLM_lpage">1918</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm200712h&amp;key=8946930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm200712h&amp;key=1%3ACAS%3A280%3ADyaK2s7gt1Kqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1996&pages=1911-1918&issue=12&author=M.+Nakaoauthor=S.+Yokotaauthor=T.+Iwaiauthor=H.+Kanekoauthor=S.+Horiikeauthor=K.+Kashimaauthor=Y.+Sonodaauthor=T.+Fujimotoauthor=S.+Misawa&title=Internal+tandem+duplication+of+the+flt3+gene+found+in+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Internal tandem duplication of the flt3 gene found in acute myeloid leukemia</span></div><div class="casAuthors">Nakao M; Yokota S; Iwai T; Kaneko H; Horiike S; Kashima K; Sonoda Y; Fujimoto T; Misawa S</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1911-8</span>
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    </div><div class="casAbstract">We analyzed mRNA expression of the flt3 gene in 30 patients with acute myeloid leukemia (AML) and 50 with acute lymphoblastic leukemia (ALL).  Using reverse transcriptase-polymerase chain reaction (RT-PCR), expression of flt3 was observed in 61 patients; 22 (73%) with AML and 39 (78%) with ALL.  Among these, five patients with AML (one M2, two M4, and two M5) showed unexpected longer transcripts with a primer combination which could amplify the transmembrane (TM) domain through the juxtamembrane (JM) domain.  For those patients who expressed flt3 mRNA, the extracellular domain of the flt3 gene was also examined by RT-PCR, but no length abnormality was seen in this region.  We further analyzed the TM domain through the second tyrosine kinase domain by genomic amplifications.  The five patients who showed aberrant flt3 transcripts exhibited abnormal longer PCR products in addition to the germline products at a region corresponding to the JM through the first TK (TK1) domains.  Sequence analyses of the abnormal RT-PCR products demonstrated that partial sequences were tandemly duplicated.  Because all these altered transcripts were in-frame, deduced protein products could be expected.  Sequence analyses of the genomic DNA revealed that three of the five patients showed a simple internal duplication within exon 11; one had an internal duplication (26 bp) with a 4-bp insertion; and in the fifth patient, a 136-bp sequence from the 3' part of exon 11 to intron 11 and the first 16-bp sequence of exon 12 were each duplicated with 1-bp insertion.  In order to confirm the tumor specificity of these alterations, DNA samples obtained at complete remission were also analyzed in the three patients harboring an flt3 duplication, but no abnormal PCR product other than germline was detected in any of the samples.  Our results suggest that an internal tandem duplication at the JM/TK1 domains of the flt3 gene is a somatic change detected preferentially in AML, possibly containing a monocytic component.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQL5G2hUkeODSA3UY9EwTNrfW6udTcc2eaxvo1J5bR3zbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2s7gt1Kqsg%253D%253D&md5=da0c7f21e6c4daf68bd4b1ae38a92891</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNakao%26aufirst%3DM.%26aulast%3DYokota%26aufirst%3DS.%26aulast%3DIwai%26aufirst%3DT.%26aulast%3DKaneko%26aufirst%3DH.%26aulast%3DHoriike%26aufirst%3DS.%26aulast%3DKashima%26aufirst%3DK.%26aulast%3DSonoda%26aufirst%3DY.%26aulast%3DFujimoto%26aufirst%3DT.%26aulast%3DMisawa%26aufirst%3DS.%26atitle%3DInternal%2520tandem%2520duplication%2520of%2520the%2520flt3%2520gene%2520found%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeukemia%26date%3D1996%26volume%3D10%26issue%3D12%26spage%3D1911%26epage%3D1918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Quentmeier, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reinhardt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaborski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drexler, H. G.</span><span> </span><span class="NLM_article-title">FLT3 mutations in acute myeloid leukemia cell lines</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">120</span><span class="NLM_x">–</span> <span class="NLM_lpage">124</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2003&pages=120-124&author=H.+Quentmeierauthor=J.+Reinhardtauthor=M.+Zaborskiauthor=H.+G.+Drexler&title=FLT3+mutations+in+acute+myeloid+leukemia+cell+lines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DQuentmeier%26aufirst%3DH.%26aulast%3DReinhardt%26aufirst%3DJ.%26aulast%3DZaborski%26aufirst%3DM.%26aulast%3DDrexler%26aufirst%3DH.%2BG.%26atitle%3DFLT3%2520mutations%2520in%2520acute%2520myeloid%2520leukemia%2520cell%2520lines%26jtitle%3DLeukemia%26date%3D2003%26volume%3D17%26spage%3D120%26epage%3D124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Yamamoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiyoi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakano, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodera, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyawaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asou, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yagasaki, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimazaki, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akiyama, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saito, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishimura, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Motoji, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shinagawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeshita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saito, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueda, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohno, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoe, T.</span><span> </span><span class="NLM_article-title">Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">2434</span><span class="NLM_x">–</span> <span class="NLM_lpage">2439</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2001&pages=2434-2439&author=Y.+Yamamotoauthor=H.+Kiyoiauthor=Y.+Nakanoauthor=R.+Suzukiauthor=Y.+Koderaauthor=S.+Miyawakiauthor=N.+Asouauthor=K.+Kuriyamaauthor=F.+Yagasakiauthor=C.+Shimazakiauthor=H.+Akiyamaauthor=K.+Saitoauthor=M.+Nishimuraauthor=T.+Motojiauthor=K.+Shinagawaauthor=A.+Takeshitaauthor=H.+Saitoauthor=R.+Uedaauthor=R.+Ohnoauthor=T.+Naoe&title=Activating+mutation+of+D835+within+the+activation+loop+of+FLT3+in+human+hematologic+malignancies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DY.%26aulast%3DKiyoi%26aufirst%3DH.%26aulast%3DNakano%26aufirst%3DY.%26aulast%3DSuzuki%26aufirst%3DR.%26aulast%3DKodera%26aufirst%3DY.%26aulast%3DMiyawaki%26aufirst%3DS.%26aulast%3DAsou%26aufirst%3DN.%26aulast%3DKuriyama%26aufirst%3DK.%26aulast%3DYagasaki%26aufirst%3DF.%26aulast%3DShimazaki%26aufirst%3DC.%26aulast%3DAkiyama%26aufirst%3DH.%26aulast%3DSaito%26aufirst%3DK.%26aulast%3DNishimura%26aufirst%3DM.%26aulast%3DMotoji%26aufirst%3DT.%26aulast%3DShinagawa%26aufirst%3DK.%26aulast%3DTakeshita%26aufirst%3DA.%26aulast%3DSaito%26aufirst%3DH.%26aulast%3DUeda%26aufirst%3DR.%26aulast%3DOhno%26aufirst%3DR.%26aulast%3DNaoe%26aufirst%3DT.%26atitle%3DActivating%2520mutation%2520of%2520D835%2520within%2520the%2520activation%2520loop%2520of%2520FLT3%2520in%2520human%2520hematologic%2520malignancies%26jtitle%3DBlood%26date%3D2001%26volume%3D97%26spage%3D2434%26epage%3D2439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Beran, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luthra, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estey, E.</span><span> </span><span class="NLM_article-title">FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotype</span> <span class="citation_source-journal">Leuk. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">547</span><span class="NLM_x">–</span> <span class="NLM_lpage">550</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm200712h&amp;key=10.1016%2Fj.leukres.2003.09.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm200712h&amp;key=15120929" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm200712h&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjs1eqtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2004&pages=547-550&author=M.+Beranauthor=R.+Luthraauthor=H.+Kantarjianauthor=E.+Estey&title=FLT3+mutation+and+response+to+intensive+chemotherapy+in+young+adult+and+elderly+patients+with+normal+karyotype"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotype</span></div><div class="casAuthors">Beran, Miloslav; Luthra, Rajyalakshmi; Kantarjian, Hagop; Estey, Elihu</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">547-550</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">The prognostic impact of FLT3 mutations on the outcome of patients with diploid AML, treated with intensive chemotherapy, was analyzed.  In 176 patients, the frequency of single ITD was 30% (<61 yr: 37%, >60 yr: 23%), single D835 mutation 2.3%, and both 2.3%.  There was no assocn. between ITD and CR rate.  ITD-pos. patients <61 yr had a higher frequency of resistant disease.  ITD was adversely assocd. with CR duration and survival in both younger and elderly patients treated with comparable chemotherapy but the effect was less in the elderly.  Presence of both ITD and D835 heralded the least favorable outcome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOs5WEiyytUbVg90H21EOLACvtfcHk0liZhnn3E_u02Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjs1eqtbs%253D&md5=c3ca274f61e2cad6cd3ac694f4b38e7f</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2003.09.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2003.09.016%26sid%3Dliteratum%253Aachs%26aulast%3DBeran%26aufirst%3DM.%26aulast%3DLuthra%26aufirst%3DR.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DEstey%26aufirst%3DE.%26atitle%3DFLT3%2520mutation%2520and%2520response%2520to%2520intensive%2520chemotherapy%2520in%2520young%2520adult%2520and%2520elderly%2520patients%2520with%2520normal%2520karyotype%26jtitle%3DLeuk.%2520Res.%26date%3D2004%26volume%3D28%26spage%3D547%26epage%3D550" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Kottaridis, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gale, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linch, D. C.</span><span> </span><span class="NLM_article-title">Prognostic implications of the presence of FLT3 mutations in patients with acute myeloid leukemia</span> <span class="citation_source-journal">Leuk. Lymphoma</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">905</span><span class="NLM_x">–</span> <span class="NLM_lpage">913</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm200712h&amp;key=10.1080%2F1042819031000067503" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm200712h&amp;key=12854887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm200712h&amp;key=1%3ACAS%3A528%3ADC%252BD3sXit1yqsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2003&pages=905-913&author=P.+D.+Kottaridisauthor=R.+E.+Galeauthor=D.+C.+Linch&title=Prognostic+implications+of+the+presence+of+FLT3+mutations+in+patients+with+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Prognostic Implications of the Presence of FLT3 Mutations in Patients with Acute Myeloid Leukemia</span></div><div class="casAuthors">Kottaridis, Panagiotis D.; Gale, Rosemary E.; Linch, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia & Lymphoma</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">905-913</span>CODEN:
                <span class="NLM_cas:coden">LELYEA</span>;
        ISSN:<span class="NLM_cas:issn">1042-8194</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Several studies have shown that mutations in the FLT3 gene are common events in AML, with approx. one third of adult patients harboring either an internal tandem duplication in the juxtramembrane domain or a D835 mutation in the kinase domain.  The majority of studies in pediatric and adult AML have shown that FLT3 mutations are powerful prognostic factors predicting for increased relapse risk and adverse overall survival.  Some reports have suggested that loss of the wild type allele might be assocd. with an even worse prognosis.  Changes in the pattern of FLT3 mutations between disease presentation and relapse restrict their value as a marker of minimal residual disease, and have significant implications for therapy.  The optimum treatment for patients with FLT3 mutations remains unknown and large prospective studies are warranted to evaluate the efficacy of various treatment modalities such as bone marrow transplantation and targeted therapy with tyrosine kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQTwjPfq-GmbVg90H21EOLACvtfcHk0lhVVtx3Ld3LDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXit1yqsLY%253D&md5=a8e8475402ecf5d5600a0e4ed7a5fdb3</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1080%2F1042819031000067503&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F1042819031000067503%26sid%3Dliteratum%253Aachs%26aulast%3DKottaridis%26aufirst%3DP.%2BD.%26aulast%3DGale%26aufirst%3DR.%2BE.%26aulast%3DLinch%26aufirst%3DD.%2BC.%26atitle%3DPrognostic%2520implications%2520of%2520the%2520presence%2520of%2520FLT3%2520mutations%2520in%2520patients%2520with%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeuk.%2520Lymphoma%26date%3D2003%26volume%3D44%26spage%3D905%26epage%3D913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Cheng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paz, K.</span><span> </span><span class="NLM_article-title">Tandutinib, an oral, small-molecule inhibitor of FLT3 for the treatment of AML and other cancer indications</span> <span class="citation_source-journal">IDrugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">46</span><span class="NLM_x">–</span> <span class="NLM_lpage">56</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm200712h&amp;key=18175263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm200712h&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitV2nsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2008&pages=46-56&issue=1&author=Y.+Chengauthor=K.+Paz&title=Tandutinib%2C+an+oral%2C+small-molecule+inhibitor+of+FLT3+for+the+treatment+of+AML+and+other+cancer+indications"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Tandutinib, an oral, small-molecule inhibitor of FLT3 for the treatment of AML and other cancer indications</span></div><div class="casAuthors">Cheng, Yuan; Paz, Keren</div><div class="citationInfo"><span class="NLM_cas:title">IDrugs</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">46-56</span>CODEN:
                <span class="NLM_cas:coden">IDRUFN</span>;
        ISSN:<span class="NLM_cas:issn">1369-7056</span>.
    
            (<span class="NLM_cas:orgname">Thomson Scientific</span>)
        </div><div class="casAbstract">A review.  An improved understanding of acute myelogenous leukemia (AML) over the past two decades has led to a characterization of assocd. recurring cytogenetic abnormalities.  AML is often driven by the overexpression or constitutive activation of receptor tyrosine kinases such as Fms-like tyrosine kinase 3 (FLT3), which serves as a good therapeutic target.  Millennium Pharmaceuticals Inc's tandutinib (MLN-518) is an orally active inhibitor of FLT3 kinase and family members PDGFRβ and c-Kit.  Tandutinib inhibited FLT3 phosphorylation, downstream signaling and malignant growth in vitro and in animal models.  The drug exhibited limited activity as a single agent in phase I and II clin. trials in patients with AML and myelodysplastic syndrome, but displayed promising antileukemic activity (90% complete remissions) in a phase I/II trial in patients with newly diagnosed AML when administered in combination with cytarabine and daunorubicin.  Phase II clin. trials for tandutinib are ongoing in patients with AML or renal cell carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVck99MEofJbVg90H21EOLACvtfcHk0lhVVtx3Ld3LDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitV2nsbo%253D&md5=aee8839e19069c5193d364832a9797e5</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DPaz%26aufirst%3DK.%26atitle%3DTandutinib%252C%2520an%2520oral%252C%2520small-molecule%2520inhibitor%2520of%2520FLT3%2520for%2520the%2520treatment%2520of%2520AML%2520and%2520other%2520cancer%2520indications%26jtitle%3DIDrugs%26date%3D2008%26volume%3D11%26issue%3D1%26spage%3D46%26epage%3D56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Levis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tse, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baldwin, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones-Brolin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dionne, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, D. A.</span><span> </span><span class="NLM_article-title">FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">3885</span><span class="NLM_x">–</span> <span class="NLM_lpage">3891</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=3885-3891&issue=11&author=M.+Levisauthor=K.+F.+Tseauthor=R.+Zhengauthor=B.+R.+Baldwinauthor=B.+D.+Smithauthor=S.+Jones-Brolinauthor=B.+Ruggeriauthor=C.+Dionneauthor=D.+A.+Small&title=FLT3-targeted+tyrosine+kinase+inhibitor+is+cytotoxic+to+leukemia+cells+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DTse%26aufirst%3DK.%2BF.%26aulast%3DZheng%26aufirst%3DR.%26aulast%3DBaldwin%26aufirst%3DB.%2BR.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DJones-Brolin%26aufirst%3DS.%26aulast%3DRuggeri%26aufirst%3DB.%26aulast%3DDionne%26aufirst%3DC.%26aulast%3DSmall%26aufirst%3DD.%2BA.%26atitle%3DFLT3-targeted%2520tyrosine%2520kinase%2520inhibitor%2520is%2520cytotoxic%2520to%2520leukemia%2520cells%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBlood%26date%3D2002%26volume%3D99%26issue%3D11%26spage%3D3885%26epage%3D3891" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">O'Farrell, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abrams, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ngai, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louie, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yee, K. W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Town, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smolich, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manning, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherrington, J. M.</span><span> </span><span class="NLM_article-title">SU11248 is a novel FLT3 tyrosine kinase with potent activity in vitro and in vivo</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">3597</span><span class="NLM_x">–</span> <span class="NLM_lpage">3605</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2003&pages=3597-3605&issue=9&author=A.+M.+O%27Farrellauthor=T.+J.+Abramsauthor=H.+A.+Yuenauthor=T.+J.+Ngaiauthor=S.+G.+Louieauthor=K.+W.+H.+Yeeauthor=L.+M.+Wongauthor=W.+Hongauthor=L.+B.+Leeauthor=A.+Townauthor=B.+D.+Smolichauthor=W.+C.+Manningauthor=L.+J.+Murrayauthor=M.+C.+Heinrichauthor=J.+M.+Cherrington&title=SU11248+is+a+novel+FLT3+tyrosine+kinase+with+potent+activity+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%2527Farrell%26aufirst%3DA.%2BM.%26aulast%3DAbrams%26aufirst%3DT.%2BJ.%26aulast%3DYuen%26aufirst%3DH.%2BA.%26aulast%3DNgai%26aufirst%3DT.%2BJ.%26aulast%3DLouie%26aufirst%3DS.%2BG.%26aulast%3DYee%26aufirst%3DK.%2BW.%2BH.%26aulast%3DWong%26aufirst%3DL.%2BM.%26aulast%3DHong%26aufirst%3DW.%26aulast%3DLee%26aufirst%3DL.%2BB.%26aulast%3DTown%26aufirst%3DA.%26aulast%3DSmolich%26aufirst%3DB.%2BD.%26aulast%3DManning%26aufirst%3DW.%2BC.%26aulast%3DMurray%26aufirst%3DL.%2BJ.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DCherrington%26aufirst%3DJ.%2BM.%26atitle%3DSU11248%2520is%2520a%2520novel%2520FLT3%2520tyrosine%2520kinase%2520with%2520potent%2520activity%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBlood%26date%3D2003%26volume%3D101%26issue%3D9%26spage%3D3597%26epage%3D3605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Mori, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreef, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravandi, F.</span><span> </span><span class="NLM_article-title">Potential role of sorafenib in the treatment of acute myeloid leukemia</span> <span class="citation_source-journal">Leuk. Lymphoma</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">2246</span><span class="NLM_x">–</span> <span class="NLM_lpage">2255</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm200712h&amp;key=10.1080%2F10428190802510349" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm200712h&amp;key=19052971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm200712h&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVKjsr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2008&pages=2246-2255&issue=12&author=S.+Moriauthor=J.+Cortesauthor=H.+Kantarjianauthor=W.+Zhangauthor=M.+Andreefauthor=F.+Ravandi&title=Potential+role+of+sorafenib+in+the+treatment+of+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Potential role of sorafenib in the treatment of acute myeloid leukemia</span></div><div class="casAuthors">Mori, Shahram; Cortes, Jorge; Kantarjian, Hagop; Zhang, Weiguo; Andreef, Michael; Ravandi, Farhad</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia & Lymphoma</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2246-2255</span>CODEN:
                <span class="NLM_cas:coden">LELYEA</span>;
        ISSN:<span class="NLM_cas:issn">1042-8194</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  The identification of aberrant cellular pathways and dysfunctional mols. important in neoplastic transformation has begun to provide us with a no. of targets for drug development.  It is likely that many of these agents will be incorporated into our existing treatment strategies that include cytotoxic agents.  Sorafenib, a multi-kinase inhibitor has been approved in the United States for the treatment of renal cell carcinoma as well as hepatocellular cancer.  Its potential role in hematol. malignancies, particularly acute myeloid leukemia (AML) is under evaluation.  Here we describe the biol. pathways in AML that are the potential targets of sorafenib action and discuss the early clin. data with the agent in solid tumors and AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmEcMC8shxmbVg90H21EOLACvtfcHk0lgDPmMNbiMHKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVKjsr%252FN&md5=0fb05e7866581d2f4f5c4f70204756c5</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1080%2F10428190802510349&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10428190802510349%26sid%3Dliteratum%253Aachs%26aulast%3DMori%26aufirst%3DS.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DAndreef%26aufirst%3DM.%26aulast%3DRavandi%26aufirst%3DF.%26atitle%3DPotential%2520role%2520of%2520sorafenib%2520in%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeuk.%2520Lymphoma%26date%3D2008%26volume%3D49%26issue%3D12%26spage%3D2246%26epage%3D2255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Kindler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipka, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, T.</span><span> </span><span class="NLM_article-title">FLT3 as a therapeutic target: still challenging after all these years</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x"> (</span><span class="NLM_issue">24</span><span class="NLM_x">) </span> <span class="NLM_fpage">5089</span><span class="NLM_x">–</span> <span class="NLM_lpage">5102</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2010&pages=5089-5102&issue=24&author=T.+Kindlerauthor=D.+B.+Lipkaauthor=T.+Fischer&title=FLT3+as+a+therapeutic+target%3A+still+challenging+after+all+these+years"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKindler%26aufirst%3DT.%26aulast%3DLipka%26aufirst%3DD.%2BB.%26aulast%3DFischer%26aufirst%3DT.%26atitle%3DFLT3%2520as%2520a%2520therapeutic%2520target%253A%2520still%2520challenging%2520after%2520all%2520these%2520years%26jtitle%3DBlood%26date%3D2010%26volume%3D116%26issue%3D24%26spage%3D5089%26epage%3D5102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Pratz, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roboz, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arowojolu, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stine, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiotsu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shudo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akinaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M.</span><span> </span><span class="NLM_article-title">A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">3938</span><span class="NLM_x">–</span> <span class="NLM_lpage">3946</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=3938-3946&author=K.+W.+Pratzauthor=J.+Cortesauthor=G.+J.+Robozauthor=N.+Raoauthor=O.+Arowojoluauthor=A.+Stineauthor=Y.+Shiotsuauthor=A.+Shudoauthor=S.+Akinagaauthor=D.+Smallauthor=J.+E.+Karpauthor=M.+Levis&title=A+pharmacodynamic+study+of+the+FLT3+inhibitor+KW-2449+yields+insight+into+the+basis+for+clinical+response"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPratz%26aufirst%3DK.%2BW.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DRoboz%26aufirst%3DG.%2BJ.%26aulast%3DRao%26aufirst%3DN.%26aulast%3DArowojolu%26aufirst%3DO.%26aulast%3DStine%26aufirst%3DA.%26aulast%3DShiotsu%26aufirst%3DY.%26aulast%3DShudo%26aufirst%3DA.%26aulast%3DAkinaga%26aufirst%3DS.%26aulast%3DSmall%26aufirst%3DD.%26aulast%3DKarp%26aufirst%3DJ.%2BE.%26aulast%3DLevis%26aufirst%3DM.%26atitle%3DA%2520pharmacodynamic%2520study%2520of%2520the%2520FLT3%2520inhibitor%2520KW-2449%2520yields%2520insight%2520into%2520the%2520basis%2520for%2520clinical%2520response%26jtitle%3DBlood%26date%3D2009%26volume%3D113%26spage%3D3938%26epage%3D3946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Stone, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeAngelo, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klimek, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galinsky, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estey, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nimer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grandin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebwohl, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">54</span><span class="NLM_x">–</span> <span class="NLM_lpage">60</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2005&pages=54-60&issue=1&author=R.+M.+Stoneauthor=D.+J.+DeAngeloauthor=V.+Klimekauthor=I.+Galinskyauthor=E.+Esteyauthor=S.+D.+Nimerauthor=W.+Grandinauthor=D.+Lebwohlauthor=Y.+Wangauthor=P.+Cohenauthor=E.+A.+Foxauthor=D.+Neubergauthor=J.+Clarkauthor=D.+G.+Gillilandauthor=J.+D.+Griffin&title=Patients+with+acute+myeloid+leukemia+and+an+activating+mutation+in+FLT3+respond+to+a+small-molecule+FLT3+tyrosine+kinase+inhibitor%2C+PKC412"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DDeAngelo%26aufirst%3DD.%2BJ.%26aulast%3DKlimek%26aufirst%3DV.%26aulast%3DGalinsky%26aufirst%3DI.%26aulast%3DEstey%26aufirst%3DE.%26aulast%3DNimer%26aufirst%3DS.%2BD.%26aulast%3DGrandin%26aufirst%3DW.%26aulast%3DLebwohl%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DFox%26aufirst%3DE.%2BA.%26aulast%3DNeuberg%26aufirst%3DD.%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DPatients%2520with%2520acute%2520myeloid%2520leukemia%2520and%2520an%2520activating%2520mutation%2520in%2520FLT3%2520respond%2520to%2520a%2520small-molecule%2520FLT3%2520tyrosine%2520kinase%2520inhibitor%252C%2520PKC412%26jtitle%3DBlood%26date%3D2005%26volume%3D105%26issue%3D1%26spage%3D54%26epage%3D60" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunawardane, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cramer, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brigham, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belli, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karaman, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pratz, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sprankle, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armstrong, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhagwat, S. S.</span><span> </span><span class="NLM_article-title">AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x"> (</span><span class="NLM_issue">14</span><span class="NLM_x">) </span> <span class="NLM_fpage">2984</span><span class="NLM_x">–</span> <span class="NLM_lpage">2992</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=2984-2992&issue=14&author=P.+P.+Zarrinkarauthor=R.+N.+Gunawardaneauthor=M.+D.+Cramerauthor=M.+F.+Gardnerauthor=D.+Brighamauthor=B.+Belliauthor=M.+W.+Karamanauthor=K.+W.+Pratzauthor=G.+Pallaresauthor=Q.+Chaoauthor=K.+G.+Sprankleauthor=H.+K.+Patelauthor=M.+Levisauthor=R.+C.+Armstrongauthor=J.+Jamesauthor=S.+S.+Bhagwat&title=AC220+is+a+uniquely+potent+and+selective+inhibitor+of+FLT3+for+the+treatment+of+acute+myeloid+leukemia+%28AML%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DGunawardane%26aufirst%3DR.%2BN.%26aulast%3DCramer%26aufirst%3DM.%2BD.%26aulast%3DGardner%26aufirst%3DM.%2BF.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DBelli%26aufirst%3DB.%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DPratz%26aufirst%3DK.%2BW.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DChao%26aufirst%3DQ.%26aulast%3DSprankle%26aufirst%3DK.%2BG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DArmstrong%26aufirst%3DR.%2BC.%26aulast%3DJames%26aufirst%3DJ.%26aulast%3DBhagwat%26aufirst%3DS.%2BS.%26atitle%3DAC220%2520is%2520a%2520uniquely%2520potent%2520and%2520selective%2520inhibitor%2520of%2520FLT3%2520for%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%2520%2528AML%2529%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26issue%3D14%26spage%3D2984%26epage%3D2992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Dunstan, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rihs, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widmer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dziadulewicz, E. K.</span><span> </span><span class="NLM_article-title">Concise and regiospecific syntheses of tri-substituted 1,2,4-triazoles</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">7983</span><span class="NLM_x">–</span> <span class="NLM_lpage">7986</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1998&pages=7983-7986&author=A.+R.+Dunstanauthor=H.+P.+Weberauthor=G.+Rihsauthor=H.+Widmerauthor=E.+K.+Dziadulewicz&title=Concise+and+regiospecific+syntheses+of+tri-substituted+1%2C2%2C4-triazoles"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDunstan%26aufirst%3DA.%2BR.%26aulast%3DWeber%26aufirst%3DH.%2BP.%26aulast%3DRihs%26aufirst%3DG.%26aulast%3DWidmer%26aufirst%3DH.%26aulast%3DDziadulewicz%26aufirst%3DE.%2BK.%26atitle%3DConcise%2520and%2520regiospecific%2520syntheses%2520of%2520tri-substituted%25201%252C2%252C4-triazoles%26jtitle%3DTetrahedron%2520Lett.%26date%3D1998%26volume%3D39%26spage%3D7983%26epage%3D7986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Davies, R. J.; Forster, C. J.; Arnost, M. J.; Wang, J.</span><span> </span><span class="NLM_article-title">Triazoles useful as inhibitors of protein kinases and their preparation, pharmaceutical compositions, and use for treatment of various disorders</span>, WO 2006047256 A1 20060504.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Davies%2C+R.+J.%3B+Forster%2C+C.+J.%3B+Arnost%2C+M.+J.%3B+Wang%2C+J.+Triazoles+useful+as+inhibitors+of+protein+kinases+and+their+preparation%2C+pharmaceutical+compositions%2C+and+use+for+treatment+of+various+disorders%2C+WO+2006047256+A1+20060504."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DR.%2BJ.%26atitle%3DTriazoles%2520useful%2520as%2520inhibitors%2520of%2520protein%2520kinases%2520and%2520their%2520preparation%252C%2520pharmaceutical%2520compositions%252C%2520and%2520use%2520for%2520treatment%2520of%2520various%2520disorders" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Heidary, D. K.; Huang, G.; Ma, J.; Boucher, D.; Forster, C.; Grey, R.; Xu, J.; Chen, G.; Zhou, J.; Namchuk, M.; Yao, M.; Stack, J.; Ball, E. D.; Davies, R. J.; Henkel, G.</span><span> </span><span class="NLM_article-title">VX-322: A Novel Dual Receptor Tyrosine Kinase Inhibitor for the Treatment of AML</span>. J. Med. Chem.<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">, </span>not supplied. </span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=D.+K.+Heidary&author=G.+Huang&author=J.+Ma&author=D.+Boucher&author=C.+Forster&author=R.+Grey&author=J.+Xu&author=G.+Chen&author=J.+Zhou&author=M.+Namchuk&author=M.+Yao&author=J.+Stack&author=E.+D.+Ball&author=R.+J.+Davies&author=G.+Henkel&title=VX-322%3A+A+Novel+Dual+Receptor+Tyrosine+Kinase+Inhibitor+for+the+Treatment+of+AML"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DHeidary%26aufirst%3DD.%2BK.%26atitle%3DVX-322%253A%2520A%2520Novel%2520Dual%2520Receptor%2520Tyrosine%2520Kinase%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520AML%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="note"><p class="first last">Primary leukemic blasts isolated from peripheral blood of AML patients were characterized for FLT3 mutations by RT-PCR and for cell-surface expression of FLT3, KIT, and the hematopoietic precursor marker CD34 by flow cytometry. FLT3 and KIT-positive blasts from four patients were incubated for 72 h with compound in the presence of human serum, FL, SCF, and GM-CSF, and then, viability was measured by ATP-luciferase assay.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">McTigue, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wickersham, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinko, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parast, C. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tempczyk-Russell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gehring, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kan, C.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villafranca, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Appelt, K.</span><span> </span><span class="NLM_article-title">Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: A key enzyme in angiogenesis</span> <span class="citation_source-journal">Structure</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">319</span><span class="NLM_x">–</span> <span class="NLM_lpage">330</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1999&pages=319-330&author=M.+A.+McTigueauthor=J.+A.+Wickershamauthor=C.+Pinkoauthor=R.+E.+Showalterauthor=C.+V.+Parastauthor=A.+Tempczyk-Russellauthor=M.+R.+Gehringauthor=B.+Mroczkowskiauthor=C.-C.+Kanauthor=J.+E.+Villafrancaauthor=K.+Appelt&title=Crystal+structure+of+the+kinase+domain+of+human+vascular+endothelial+growth+factor+receptor+2%3A+A+key+enzyme+in+angiogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMcTigue%26aufirst%3DM.%2BA.%26aulast%3DWickersham%26aufirst%3DJ.%2BA.%26aulast%3DPinko%26aufirst%3DC.%26aulast%3DShowalter%26aufirst%3DR.%2BE.%26aulast%3DParast%26aufirst%3DC.%2BV.%26aulast%3DTempczyk-Russell%26aufirst%3DA.%26aulast%3DGehring%26aufirst%3DM.%2BR.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DKan%26aufirst%3DC.-C.%26aulast%3DVillafranca%26aufirst%3DJ.%2BE.%26aulast%3DAppelt%26aufirst%3DK.%26atitle%3DCrystal%2520structure%2520of%2520the%2520kinase%2520domain%2520of%2520human%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%25202%253A%2520A%2520key%2520enzyme%2520in%2520angiogenesis%26jtitle%3DStructure%26date%3D1999%26volume%3D3%26spage%3D319%26epage%3D330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Griffith, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faerman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swenson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wynn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippke, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saxena, K.</span><span> </span><span class="NLM_article-title">The Structural Basis for Autoinhibition of FLT3 by the Juxtamembrane Domain</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">178</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm200712h&amp;key=10.1016%2FS1097-2765%2803%2900505-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm200712h&amp;key=14759363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm200712h&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFOiu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2004&pages=169-178&author=J.+Griffithauthor=J.+Blackauthor=C.+Faermanauthor=L.+Swensonauthor=M.+Wynnauthor=F.+Luauthor=J.+Lippkeauthor=K.+Saxena&title=The+Structural+Basis+for+Autoinhibition+of+FLT3+by+the+Juxtamembrane+Domain"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">The structural basis for autoinhibition of FLT3 by the juxtamembrane domain</span></div><div class="casAuthors">Griffith, James; Black, James; Faerman, Carlos; Swenson, Lora; Wynn, Michael; Lu, Fan; Lippke, Judith; Saxena, Kumkum</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">169-178</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">FLT3 is a type III receptor tyrosine kinase that is thought to play a key role in hematopoiesis.  Certain classes of FLT3 mutations cause constitutively activated forms of the receptor that are found in significant nos. of patients with acute myelogenous leukemia (AML).  The mutations occur either in the activation loop, for example, as point mutations of Asp835 or as internal tandem duplication (ITD) sequences in the juxtamembrane (JM) domain.  To further understand the nature of FLT3 autoinhibition and regulation, we have detd. the crystal structure of the autoinhibited form of FLT3.  This structure shows the autoinhibitory conformation of a complete JM domain in this class of receptor tyrosine kinases.  The detailed inhibitory mechanism of the JM domain is revealed, which is likely utilized by other members of type III receptor tyrosine kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJAabT6TBxpLVg90H21EOLACvtfcHk0lgsuS5044pLQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFOiu7g%253D&md5=d1df4a37aac59f5b59ca242fc8ccd6da</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2FS1097-2765%2803%2900505-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1097-2765%252803%252900505-7%26sid%3Dliteratum%253Aachs%26aulast%3DGriffith%26aufirst%3DJ.%26aulast%3DBlack%26aufirst%3DJ.%26aulast%3DFaerman%26aufirst%3DC.%26aulast%3DSwenson%26aufirst%3DL.%26aulast%3DWynn%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DF.%26aulast%3DLippke%26aufirst%3DJ.%26aulast%3DSaxena%26aufirst%3DK.%26atitle%3DThe%2520Structural%2520Basis%2520for%2520Autoinhibition%2520of%2520FLT3%2520by%2520the%2520Juxtamembrane%2520Domain%26jtitle%3DMol.%2520Cell%26date%3D2004%26volume%3D13%26spage%3D169%26epage%3D178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span> <span class="citation_source-book">Molecular Operating Environment</span> (MOE, version 2002.03); <span class="NLM_publisher-name">Chemical Computing Group</span>: <span class="NLM_publisher-loc">Montreal, PQ, Canada</span>,<span class="NLM_x"> </span><span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Molecular+Operating+Environment+%28MOE%2C+version+2002.03%29%3B+Chemical+Computing+Group%3A+Montreal%2C+PQ%2C+Canada%2C+2002."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DMolecular%2520Operating%2520Environment%26pub%3DChemical%2520Computing%2520Group%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':[],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 14 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hwangseo  Park</span>, <span class="hlFld-ContribAuthor ">Soyoung  Lee</span>, and <span class="hlFld-ContribAuthor ">Sungwoo  Hong</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Dual Inhibitors for Wild Type and D816V Mutant of c-KIT Kinase through Virtual and Biochemical Screening of Natural Products. </span><span class="cited-content_cbyCitation_journal-name">Journal of Natural Products</span><span> <strong>2016,</strong> <em>79 </em>
                                    (2)
                                     , 293-299. <a href="https://doi.org/10.1021/acs.jnatprod.5b00851" title="DOI URL">https://doi.org/10.1021/acs.jnatprod.5b00851</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jnatprod.5b00851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jnatprod.5b00851%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Natural%2520Products%26atitle%3DDiscovery%252Bof%252BDual%252BInhibitors%252Bfor%252BWild%252BType%252Band%252BD816V%252BMutant%252Bof%252Bc-KIT%252BKinase%252Bthrough%252BVirtual%252Band%252BBiochemical%252BScreening%252Bof%252BNatural%252BProducts%26aulast%3DPark%26aufirst%3DHwangseo%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D08102015%26date%3D25012016%26date%3D26022016%26volume%3D79%26issue%3D2%26spage%3D293%26epage%3D299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Koteswara Rao  Valasani</span>, <span class="hlFld-ContribAuthor ">Michael O.  Chaney</span>, <span class="hlFld-ContribAuthor ">Victor W.  Day</span>, and <span class="hlFld-ContribAuthor ">Shirley  ShiDu Yan</span>  . </span><span class="cited-content_cbyCitation_article-title">Acetylcholinesterase Inhibitors: Structure Based Design, Synthesis, Pharmacophore Modeling, and Virtual Screening. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2013,</strong> <em>53 </em>
                                    (8)
                                     , 2033-2046. <a href="https://doi.org/10.1021/ci400196z" title="DOI URL">https://doi.org/10.1021/ci400196z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ci400196z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fci400196z%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DAcetylcholinesterase%252BInhibitors%25253A%252BStructure%252BBased%252BDesign%25252C%252BSynthesis%25252C%252BPharmacophore%252BModeling%25252C%252Band%252BVirtual%252BScreening%26aulast%3DValasani%26aufirst%3DKoteswara%2BRao%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D02042013%26date%3D05082013%26date%3D26082013%26date%3D18062013%26volume%3D53%26issue%3D8%26spage%3D2033%26epage%3D2046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ken-ichi  Kusakabe</span>, <span class="hlFld-ContribAuthor ">Nobuyuki  Ide</span>, <span class="hlFld-ContribAuthor ">Yataro  Daigo</span>, <span class="hlFld-ContribAuthor ">Yuki  Tachibana</span>, <span class="hlFld-ContribAuthor ">Takeshi,  Itoh</span>, <span class="hlFld-ContribAuthor ">Takahiko  Yamamoto</span>, <span class="hlFld-ContribAuthor ">Hiroshi  Hashizume</span>, <span class="hlFld-ContribAuthor ">Yoshio  Hato</span>, <span class="hlFld-ContribAuthor ">Kenichi  Higashino</span>, <span class="hlFld-ContribAuthor ">Yousuke  Okano</span>, <span class="hlFld-ContribAuthor ">Yuji  Sato</span>, <span class="hlFld-ContribAuthor ">Makiko  Inoue</span>, <span class="hlFld-ContribAuthor ">Motofumi  Iguchi</span>, <span class="hlFld-ContribAuthor ">Takayuki  Kanazawa</span>, <span class="hlFld-ContribAuthor ">Yukichi  Ishioka</span>, <span class="hlFld-ContribAuthor ">Keiji  Dohi</span>, <span class="hlFld-ContribAuthor ">Yasuto  Kido</span>, <span class="hlFld-ContribAuthor ">Shingo  Sakamoto</span>, <span class="hlFld-ContribAuthor ">Kazuya  Yasuo</span>, <span class="hlFld-ContribAuthor ">Masahiro  Maeda</span>, <span class="hlFld-ContribAuthor ">Masayo  Higaki</span>, <span class="hlFld-ContribAuthor ">Kazuo  Ueda</span>, <span class="hlFld-ContribAuthor ">Hidenori  Yoshizawa</span>, <span class="hlFld-ContribAuthor ">Yoshiyasu  Baba</span>, <span class="hlFld-ContribAuthor ">Takeshi  Shiota</span>, <span class="hlFld-ContribAuthor ">Hitoshi  Murai</span>, and <span class="hlFld-ContribAuthor ">Yusuke  Nakamura</span>  . </span><span class="cited-content_cbyCitation_article-title">Indazole-Based Potent and Cell-Active Mps1 Kinase Inhibitors: Rational Design from Pan-Kinase Inhibitor Anthrapyrazolone (SP600125). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (11)
                                     , 4343-4356. <a href="https://doi.org/10.1021/jm4000215" title="DOI URL">https://doi.org/10.1021/jm4000215</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm4000215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm4000215%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIndazole-Based%252BPotent%252Band%252BCell-Active%252BMps1%252BKinase%252BInhibitors%25253A%252BRational%252BDesign%252Bfrom%252BPan-Kinase%252BInhibitor%252BAnthrapyrazolone%252B%252528SP600125%252529%26aulast%3DKusakabe%26aufirst%3DKen-ichi%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D04012013%26date%3D24052013%26date%3D13062013%26date%3D01052013%26volume%3D56%26issue%3D11%26spage%3D4343%26epage%3D4356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ling-Ling  Yang</span>, <span class="hlFld-ContribAuthor ">Guo-Bo  Li</span>, <span class="hlFld-ContribAuthor ">Shuang  Ma</span>, <span class="hlFld-ContribAuthor ">Chan  Zou</span>, <span class="hlFld-ContribAuthor ">Shu  Zhou</span>, <span class="hlFld-ContribAuthor ">Qi-Zheng  Sun</span>, <span class="hlFld-ContribAuthor ">Chuan  Cheng</span>, <span class="hlFld-ContribAuthor ">Xin  Chen</span>, <span class="hlFld-ContribAuthor ">Li-Jiao  Wang</span>, <span class="hlFld-ContribAuthor ">Shan  Feng</span>, <span class="hlFld-ContribAuthor ">Lin-Li  Li</span>, and <span class="hlFld-ContribAuthor ">Sheng-Yong  Yang</span>  . </span><span class="cited-content_cbyCitation_article-title">Structure–Activity Relationship Studies of Pyrazolo[3,4-d]pyrimidine Derivatives Leading to the Discovery of a Novel Multikinase Inhibitor That Potently Inhibits FLT3 and VEGFR2 and Evaluation of Its Activity against Acute Myeloid Leukemia in Vitro and in Vivo. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (4)
                                     , 1641-1655. <a href="https://doi.org/10.1021/jm301537p" title="DOI URL">https://doi.org/10.1021/jm301537p</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm301537p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm301537p%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure%2525E2%252580%252593Activity%252BRelationship%252BStudies%252Bof%252BPyrazolo%25255B3%25252C4-d%25255Dpyrimidine%252BDerivatives%252BLeading%252Bto%252Bthe%252BDiscovery%252Bof%252Ba%252BNovel%252BMultikinase%252BInhibitor%252BThat%252BPotently%252BInhibits%252BFLT3%252Band%252BVEGFR2%252Band%252BEvaluation%252Bof%252BIts%252BActivity%252Bagainst%252BAcute%252BMyeloid%252BLeukemia%252Bin%252BVitro%252Band%252Bin%252BVivo%26aulast%3DYang%26aufirst%3DLing-Ling%26date%3D2013%26date%3D2013%26date%3D2012%26date%3D20102012%26date%3D19022013%26date%3D28022013%26date%3D30012013%26volume%3D56%26issue%3D4%26spage%3D1641%26epage%3D1655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David K.  Heidary</span>, <span class="hlFld-ContribAuthor ">George  Huang</span>, <span class="hlFld-ContribAuthor ">Diane  Boucher</span>, <span class="hlFld-ContribAuthor ">Jianguo  Ma</span>, <span class="hlFld-ContribAuthor ">Cornelia  Forster</span>, <span class="hlFld-ContribAuthor ">Ron  Grey</span>, <span class="hlFld-ContribAuthor ">Jinwang  Xu</span>, <span class="hlFld-ContribAuthor ">Michael  Arnost</span>, <span class="hlFld-ContribAuthor ">Deborah  Choquette</span>, <span class="hlFld-ContribAuthor ">Guanjing  Chen</span>, <span class="hlFld-ContribAuthor ">Jie-Hua  Zhou</span>, <span class="hlFld-ContribAuthor ">Yung-Mae  Yao</span>, <span class="hlFld-ContribAuthor ">Edward D.  Ball</span>, <span class="hlFld-ContribAuthor ">Mark  Namchuk</span>, <span class="hlFld-ContribAuthor ">Robert J.  Davies</span>, and <span class="hlFld-ContribAuthor ">Greg  Henkel</span>  . </span><span class="cited-content_cbyCitation_article-title">VX-322: A Novel Dual Receptor Tyrosine Kinase Inhibitor for the Treatment of Acute Myelogenous Leukemia. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2012,</strong> <em>55 </em>
                                    (2)
                                     , 725-734. <a href="https://doi.org/10.1021/jm201198w" title="DOI URL">https://doi.org/10.1021/jm201198w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm201198w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm201198w%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DVX-322%25253A%252BA%252BNovel%252BDual%252BReceptor%252BTyrosine%252BKinase%252BInhibitor%252Bfor%252Bthe%252BTreatment%252Bof%252BAcute%252BMyelogenous%252BLeukemia%26aulast%3DHeidary%26aufirst%3DDavid%2BK.%26date%3D2012%26date%3D2012%26date%3D2011%26date%3D09092011%26date%3D05012012%26date%3D26012012%26volume%3D55%26issue%3D2%26spage%3D725%26epage%3D734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Reem F.  Abutayeh</span>, <span class="hlFld-ContribAuthor ">Jehad  Almaliti</span>, <span class="hlFld-ContribAuthor ">Mutasem O.  Taha</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of New Sulfonamides-Based Flt3 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Chemistry</span><span> <strong>2020,</strong> <em>16 </em>
                                    (3)
                                     , 403-412. <a href="https://doi.org/10.2174/1573406415666190401144053" title="DOI URL">https://doi.org/10.2174/1573406415666190401144053</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1573406415666190401144053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1573406415666190401144053%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Chemistry%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BNew%252BSulfonamides-Based%252BFlt3%252BInhibitors%26aulast%3DAbutayeh%26aufirst%3DReem%2BF.%26date%3D2020%26volume%3D16%26issue%3D3%26spage%3D403%26epage%3D412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pouria  Shirvani</span>, <span class="hlFld-ContribAuthor ">Afshin  Fassihi</span>, <span class="hlFld-ContribAuthor ">Lotfollah  Saghaie</span>, <span class="hlFld-ContribAuthor ">Siska  Van Belle</span>, <span class="hlFld-ContribAuthor ">Zeger  Debyser</span>, <span class="hlFld-ContribAuthor ">Frauke  Christ</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, anti-HIV-1 and antiproliferative evaluation of novel 4-nitroimidazole derivatives combined with 5-hydroxy-4-pyridinone moiety. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Structure</span><span> <strong>2020,</strong> <em>1202 </em>, 127344. <a href="https://doi.org/10.1016/j.molstruc.2019.127344" title="DOI URL">https://doi.org/10.1016/j.molstruc.2019.127344</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molstruc.2019.127344&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molstruc.2019.127344%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Structure%26atitle%3DSynthesis%25252C%252Banti-HIV-1%252Band%252Bantiproliferative%252Bevaluation%252Bof%252Bnovel%252B4-nitroimidazole%252Bderivatives%252Bcombined%252Bwith%252B5-hydroxy-4-pyridinone%252Bmoiety%26aulast%3DShirvani%26aufirst%3DPouria%26date%3D2020%26volume%3D1202%26spage%3D127344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Reem Fawaz  Abutayeh</span>, <span class="hlFld-ContribAuthor ">Mutasem O.  Taha</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel Flt3 inhibitory chemotypes through extensive ligand-based and new structure-based pharmacophore modelling methods. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Graphics and Modelling</span><span> <strong>2019,</strong> <em>88 </em>, 128-151. <a href="https://doi.org/10.1016/j.jmgm.2019.01.011" title="DOI URL">https://doi.org/10.1016/j.jmgm.2019.01.011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jmgm.2019.01.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jmgm.2019.01.011%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Graphics%2520and%2520Modelling%26atitle%3DDiscovery%252Bof%252Bnovel%252BFlt3%252Binhibitory%252Bchemotypes%252Bthrough%252Bextensive%252Bligand-based%252Band%252Bnew%252Bstructure-based%252Bpharmacophore%252Bmodelling%252Bmethods%26aulast%3DAbutayeh%26aufirst%3DReem%2BFawaz%26date%3D2019%26volume%3D88%26spage%3D128%26epage%3D151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Subba  Rao Devineni</span>, <span class="hlFld-ContribAuthor ">Madhava  Golla</span>, <span class="hlFld-ContribAuthor ">Thaslim  Basha Shaik</span>, <span class="hlFld-ContribAuthor ">Janardhan  Avilala</span>, <span class="hlFld-ContribAuthor ">Madhu  Sudhana Saddala</span>, <span class="hlFld-ContribAuthor ">Narasimha  Golla</span>, <span class="hlFld-ContribAuthor ">Naga  Raju Chamarthi</span>. </span><span class="cited-content_cbyCitation_article-title">Ethyl phosphoramidates of acyclovir: design, synthesis, molecular docking (HN Protein), and evaluation of antiviral and antioxidant activities. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Chemistry Research</span><span> <strong>2017,</strong> <em>26 </em>
                                    (5)
                                     , 999-1009. <a href="https://doi.org/10.1007/s00044-017-1819-8" title="DOI URL">https://doi.org/10.1007/s00044-017-1819-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00044-017-1819-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00044-017-1819-8%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Chemistry%2520Research%26atitle%3DEthyl%252Bphosphoramidates%252Bof%252Bacyclovir%25253A%252Bdesign%25252C%252Bsynthesis%25252C%252Bmolecular%252Bdocking%252B%252528HN%252BProtein%252529%25252C%252Band%252Bevaluation%252Bof%252Bantiviral%252Band%252Bantioxidant%252Bactivities%26aulast%3DRao%2BDevineni%26aufirst%3DSubba%26date%3D2017%26date%3D2017%26volume%3D26%26issue%3D5%26spage%3D999%26epage%3D1009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xing-Dong  Lin</span>, <span class="hlFld-ContribAuthor ">Hui-Wen  Yang</span>, <span class="hlFld-ContribAuthor ">Shuang  Ma</span>, <span class="hlFld-ContribAuthor ">Wei-Wei  Li</span>, <span class="hlFld-ContribAuthor ">Chun-Hui  Zhang</span>, <span class="hlFld-ContribAuthor ">Wen-Jing  Wang</span>, <span class="hlFld-ContribAuthor ">Rong  Xiang</span>, <span class="hlFld-ContribAuthor ">Lin-Li  Li</span>, <span class="hlFld-ContribAuthor ">Sheng-Yong  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 6-phenylimidazo[2,1-b]thiazole derivatives as a new type of FLT3 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>25 </em>
                                    (20)
                                     , 4534-4538. <a href="https://doi.org/10.1016/j.bmcl.2015.08.068" title="DOI URL">https://doi.org/10.1016/j.bmcl.2015.08.068</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2015.08.068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2015.08.068%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252B6-phenylimidazo%25255B2%25252C1-b%25255Dthiazole%252Bderivatives%252Bas%252Ba%252Bnew%252Btype%252Bof%252BFLT3%252Binhibitors%26aulast%3DLin%26aufirst%3DXing-Dong%26date%3D2015%26volume%3D25%26issue%3D20%26spage%3D4534%26epage%3D4538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jin  Xu</span>, <span class="hlFld-ContribAuthor ">Esther H.Q.  Ong</span>, <span class="hlFld-ContribAuthor ">Jeffrey  Hill</span>, <span class="hlFld-ContribAuthor ">Anqi  Chen</span>, <span class="hlFld-ContribAuthor ">Christina L.L.  Chai</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of FLT3 covalent inhibitors with a resorcylic acid core. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2014,</strong> <em>22 </em>
                                    (23)
                                     , 6625-6637. <a href="https://doi.org/10.1016/j.bmc.2014.10.006" title="DOI URL">https://doi.org/10.1016/j.bmc.2014.10.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2014.10.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2014.10.006%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252BFLT3%252Bcovalent%252Binhibitors%252Bwith%252Ba%252Bresorcylic%252Bacid%252Bcore%26aulast%3DXu%26aufirst%3DJin%26date%3D2014%26volume%3D22%26issue%3D23%26spage%3D6625%26epage%3D6637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bei  Hu</span>, <span class="hlFld-ContribAuthor ">Praveen  Vikas</span>, <span class="hlFld-ContribAuthor ">Mohamad  Mohty</span>, <span class="hlFld-ContribAuthor ">Bipin N  Savani</span>. </span><span class="cited-content_cbyCitation_article-title">Allogeneic stem cell transplantation and targeted therapy for FLT3/ITD+ acute myeloid leukemia: an update. </span><span class="cited-content_cbyCitation_journal-name">Expert Review of Hematology</span><span> <strong>2014,</strong> <em>7 </em>
                                    (2)
                                     , 301-315. <a href="https://doi.org/10.1586/17474086.2014.857596" title="DOI URL">https://doi.org/10.1586/17474086.2014.857596</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1586/17474086.2014.857596&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1586%2F17474086.2014.857596%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Review%2520of%2520Hematology%26atitle%3DAllogeneic%252Bstem%252Bcell%252Btransplantation%252Band%252Btargeted%252Btherapy%252Bfor%252BFLT3%25252FITD%25252B%252Bacute%252Bmyeloid%252Bleukemia%25253A%252Ban%252Bupdate%26aulast%3DHu%26aufirst%3DBei%26date%3D2014%26date%3D2013%26volume%3D7%26issue%3D2%26spage%3D301%26epage%3D315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A Y H  Leung</span>, <span class="hlFld-ContribAuthor ">C-H  Man</span>, <span class="hlFld-ContribAuthor ">Y-L  Kwong</span>. </span><span class="cited-content_cbyCitation_article-title">FLT3 inhibition: a moving and evolving target in acute myeloid leukaemia. </span><span class="cited-content_cbyCitation_journal-name">Leukemia</span><span> <strong>2013,</strong> <em>27 </em>
                                    (2)
                                     , 260-268. <a href="https://doi.org/10.1038/leu.2012.195" title="DOI URL">https://doi.org/10.1038/leu.2012.195</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/leu.2012.195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fleu.2012.195%26sid%3Dliteratum%253Aachs%26jtitle%3DLeukemia%26atitle%3DFLT3%252Binhibition%25253A%252Ba%252Bmoving%252Band%252Bevolving%252Btarget%252Bin%252Bacute%252Bmyeloid%252Bleukaemia%26aulast%3DLeung%26aufirst%3DA%2BY%2BH%26date%3D2013%26date%3D2012%26volume%3D27%26issue%3D2%26spage%3D260%26epage%3D268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kilaru  Ravendra Babu</span>, <span class="hlFld-ContribAuthor ">Valasani  Koteswara Rao</span>, <span class="hlFld-ContribAuthor ">Yellapu  Nanda Kumar</span>, <span class="hlFld-ContribAuthor ">Kishore  Polireddy</span>, <span class="hlFld-ContribAuthor ">Kadiam  Venkata Subbaiah</span>, <span class="hlFld-ContribAuthor ">Matcha  Bhaskar</span>, <span class="hlFld-ContribAuthor ">Valluru  Lokanatha</span>, <span class="hlFld-ContribAuthor ">Chamarthi  Naga Raju</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of substituted [3, 2-a] pyrimidines as selective antiviral agents: Molecular modeling study. </span><span class="cited-content_cbyCitation_journal-name">Antiviral Research</span><span> <strong>2012,</strong> <em>95 </em>
                                    (2)
                                     , 118-127. <a href="https://doi.org/10.1016/j.antiviral.2012.05.010" title="DOI URL">https://doi.org/10.1016/j.antiviral.2012.05.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.antiviral.2012.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.antiviral.2012.05.010%26sid%3Dliteratum%253Aachs%26jtitle%3DAntiviral%2520Research%26atitle%3DIdentification%252Bof%252Bsubstituted%252B%25255B3%25252C%252B2-a%25255D%252Bpyrimidines%252Bas%252Bselective%252Bantiviral%252Bagents%25253A%252BMolecular%252Bmodeling%252Bstudy%26aulast%3DRavendra%2BBabu%26aufirst%3DKilaru%26date%3D2012%26volume%3D95%26issue%3D2%26spage%3D118%26epage%3D127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-20/jm200712h/production/images/medium/jm-2011-00712h_0006.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-20/jm200712h/production/images/large/jm-2011-00712h_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200712h&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-20/jm200712h/production/images/medium/jm-2011-00712h_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-20/jm200712h/production/images/large/jm-2011-00712h_0009.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Compound <b>1</b> modeled into a FLT3 homology model. Hinge hydrogen bonds are shown as dashed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-20/jm200712h/production/images/large/jm-2011-00712h_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200712h&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-20/jm200712h/production/images/medium/jm-2011-00712h_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-20/jm200712h/production/images/large/jm-2011-00712h_0010.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthetic Route to the 1,2,4-Triazoles<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-20/jm200712h/production/images/large/jm-2011-00712h_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200712h&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) ArNH<sub>2</sub>, <i>i</i>-PrOH or dioxane, reflux. (b) ArNHNH<sub>2</sub>, <i>i</i>-PrOH, or CH<sub>3</sub>CN or DMA, reflux, or microwave 180–220 °C.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-20/jm200712h/production/images/medium/jm-2011-00712h_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-20/jm200712h/production/images/large/jm-2011-00712h_0011.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of 4-(4-Morpholinocyclohexyl)anilines<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-20/jm200712h/production/images/large/jm-2011-00712h_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200712h&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NO<sub>2</sub>BF<sub>4</sub>, CH<sub>3</sub>CN. (b) Morpholine, NaBH(OAc)<sub>3</sub>, THF. (c) Zn, NH<sub>4</sub>Cl, MeOH, reflux. (d) Compound <b>2</b>, iPrOH. (e) 2-Pyridylhydrazine, iPrOH, MW 180 °C.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i23">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57882" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57882" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 28 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Groves, F. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linet, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devesa, S. S.</span><span> </span><span class="NLM_article-title">Patterns of occurrence of the leukemias</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">31A</span><span class="NLM_x">, </span> <span class="NLM_fpage">941</span><span class="NLM_x">–</span> <span class="NLM_lpage">949</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31A&publication_year=1995&pages=941-949&author=F.+D.+Grovesauthor=M.+S.+Linetauthor=S.+S.+Devesa&title=Patterns+of+occurrence+of+the+leukemias"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGroves%26aufirst%3DF.%2BD.%26aulast%3DLinet%26aufirst%3DM.%2BS.%26aulast%3DDevesa%26aufirst%3DS.%2BS.%26atitle%3DPatterns%2520of%2520occurrence%2520of%2520the%2520leukemias%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D1995%26volume%3D31A%26spage%3D941%26epage%3D949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Appelbaum, F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gundacker, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Head, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slovak, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willman, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godwin, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petersdorf, S. H.</span><span> </span><span class="NLM_article-title">Age and acute myeloid leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">3481</span><span class="NLM_x">–</span> <span class="NLM_lpage">3485</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2006&pages=3481-3485&author=F.+R.+Appelbaumauthor=H.+Gundackerauthor=D.+R.+Headauthor=M.+L.+Slovakauthor=C.+L.+Willmanauthor=J.+E.+Godwinauthor=J.+E.+Andersonauthor=S.+H.+Petersdorf&title=Age+and+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAppelbaum%26aufirst%3DF.%2BR.%26aulast%3DGundacker%26aufirst%3DH.%26aulast%3DHead%26aufirst%3DD.%2BR.%26aulast%3DSlovak%26aufirst%3DM.%2BL.%26aulast%3DWillman%26aufirst%3DC.%2BL.%26aulast%3DGodwin%26aufirst%3DJ.%2BE.%26aulast%3DAnderson%26aufirst%3DJ.%2BE.%26aulast%3DPetersdorf%26aufirst%3DS.%2BH.%26atitle%3DAge%2520and%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2006%26volume%3D107%26spage%3D3481%26epage%3D3485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Brien, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faderl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jabbour, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Manero, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wierda, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierce, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estey, E.</span><span> </span><span class="NLM_article-title">Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: Predictive prognostic models for outcome</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">1090</span><span class="NLM_x">–</span> <span class="NLM_lpage">1098</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2006&pages=1090-1098&author=H.+Kantarjianauthor=S.+O%27Brienauthor=J.+Cortesauthor=F.+Gilesauthor=S.+Faderlauthor=E.+Jabbourauthor=G.+Garcia-Maneroauthor=W.+Wierdaauthor=S.+Pierceauthor=J.+Shanauthor=E.+Estey&title=Results+of+intensive+chemotherapy+in+998+patients+age+65+years+or+older+with+acute+myeloid+leukemia+or+high-risk+myelodysplastic+syndrome%3A+Predictive+prognostic+models+for+outcome"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DO%2527Brien%26aufirst%3DS.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DGiles%26aufirst%3DF.%26aulast%3DFaderl%26aufirst%3DS.%26aulast%3DJabbour%26aufirst%3DE.%26aulast%3DGarcia-Manero%26aufirst%3DG.%26aulast%3DWierda%26aufirst%3DW.%26aulast%3DPierce%26aufirst%3DS.%26aulast%3DShan%26aufirst%3DJ.%26aulast%3DEstey%26aufirst%3DE.%26atitle%3DResults%2520of%2520intensive%2520chemotherapy%2520in%2520998%2520patients%2520age%252065%2520years%2520or%2520older%2520with%2520acute%2520myeloid%2520leukemia%2520or%2520high-risk%2520myelodysplastic%2520syndrome%253A%2520Predictive%2520prognostic%2520models%2520for%2520outcome%26jtitle%3DCancer%26date%3D2006%26volume%3D106%26spage%3D1090%26epage%3D1098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Tallman, M. S.</span><span> </span><span class="NLM_article-title">New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents</span> <span class="citation_source-journal">Hematol. Am. Soc. Hematol. Educ. Program</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_fpage">143</span><span class="NLM_x">–</span> <span class="NLM_lpage">150</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm200712h&amp;key=10.1182%2Fasheducation-2005.1.143" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm200712h&amp;key=16304372" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm200712h&amp;key=1%3ACAS%3A280%3ADC%252BD2Mnit1Cgtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&pages=143-150&author=M.+S.+Tallman&title=New+strategies+for+the+treatment+of+acute+myeloid+leukemia+including+antibodies+and+other+novel+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents</span></div><div class="casAuthors">Tallman Martin S</div><div class="citationInfo"><span class="NLM_cas:title">Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">143-50</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The prognosis for younger adults (< or = 55-60 years) with acute myeloid leukemia (AML) has improved during the last four decades.  However, there has been little progress in the treatment of older adults.  This disappointing observation is important because the median age of patients with AML is about 70 years.  Approximately 60%-80% of younger adults with AML achieve complete remission (CR) with the cytotoxic agents cytarabine and an anthracycline such as daunorubicin or idarubicin or the anthracenedione mitoxantrone.  However, only 30%-40% of such patients are alive and disease-free at 5 years.  Among older adults, CR is achieved in 40%-55%, but there are very few long-term survivors.  Many studies have evaluated the impact of alternative doses and schedules, as well as additional cytotoxic drugs, on the prognosis for this group of patients.  The outcome has not improved substantially beyond that achieved with conventional doses of an anthracycline and cytarabine followed by high-dose cytarabine consolidation.Several factors identified at diagnosis can predict outcome.  The most important of these is the karyotype of the leukemic cells.  Another critical factor is the presence of transmembrane transporter proteins, which confer multidrug resistance and mutations in or overexpression of specific genes such as WT1, C/EBPalpha, BAX, and BCL-2/BAX ratio, BAALC, EVI1, KIT and FLT3.  The development of specific agents directed at gene mutations, signal transduction pathways and unique cell surface antigens provide the foundation for new therapeutic strategies.  Such agents include the immunoconjugate gemtuzumab ozogamicin, multidrug resistance inhibitors, farnesyltransferase inhibitors, histone deacetylase and proteosome inhibitors, antiangiogenesis agents, FLT3 inhibitors, apoptosis inhibitors, and nucleoside analogs.  All of these agents can potentially address the heterogeneous abnormalities in AML and significantly improve the outcome for patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS47oWJXey1eYkFb3mqPUYDfW6udTcc2eZr8s_9Dj6K-rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2Mnit1Cgtw%253D%253D&md5=7699fd99a00cfe70522bcbf5200e957d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1182%2Fasheducation-2005.1.143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fasheducation-2005.1.143%26sid%3Dliteratum%253Aachs%26aulast%3DTallman%26aufirst%3DM.%2BS.%26atitle%3DNew%2520strategies%2520for%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%2520including%2520antibodies%2520and%2520other%2520novel%2520agents%26jtitle%3DHematol.%2520Am.%2520Soc.%2520Hematol.%2520Educ.%2520Program%26date%3D2005%26spage%3D143%26epage%3D150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Kell, J.</span><span> </span><span class="NLM_article-title">Emerging treatments in acute myeloid leukaemia</span> <span class="citation_source-journal">Expert Opin. Emerging Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">55</span><span class="NLM_x">–</span> <span class="NLM_lpage">71</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm200712h&amp;key=10.1517%2F14728214.9.1.55" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm200712h&amp;key=15155136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm200712h&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkt1Ggt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=55-71&author=J.+Kell&title=Emerging+treatments+in+acute+myeloid+leukaemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging treatments in acute myeloid leukaemia</span></div><div class="casAuthors">Kell, Jonathan</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Emerging Drugs</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">55-71</span>CODEN:
                <span class="NLM_cas:coden">EOEDA3</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Acute myeloid leukemia (AML) is the most common form of leukemia in young adults.  Although 75-85% of patients will achieve complete remission after induction chemotherapy, the long-term survival is still < 50% at 5 yr.  Chemotherapy has increased in intensity in recent years and is perceived to have reached the limit of toxicity.  Allogeneic bone marrow transplantation, which is undoubtedly the most effective way to prevent relapse, may not add substantial survival benefits.  Several new pharmacol. approaches to the treatment of AML are now becoming available, with various mol. targets identified, including the farnesylation of RAS family proteins and tyrosine kinases involved in signal transduction and epigenetic methylation.  More selective delivery of chemotherapeutic agents is also feasible using humanized monoclonal antibodies, with the intriguing possibility of increasing treatment delivery without increasing the toxicity.  However, despite the progress in the rational design of drugs in disorders such as chronic myeloid leukemia, AML lacks a single specific pathognomic genetic event to act as a drug target.  This review discusses the drugs presently under investigation in Phase II or Phase III trials in AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXX3SUG1IFfbVg90H21EOLACvtfcHk0lgj_AoLG1knDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkt1Ggt7o%253D&md5=f5a92e0293b91905556ee34bafe486b9</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1517%2F14728214.9.1.55&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728214.9.1.55%26sid%3Dliteratum%253Aachs%26aulast%3DKell%26aufirst%3DJ.%26atitle%3DEmerging%2520treatments%2520in%2520acute%2520myeloid%2520leukaemia%26jtitle%3DExpert%2520Opin.%2520Emerging%2520Drugs%26date%3D2004%26volume%3D9%26spage%3D55%26epage%3D71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Banerji, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sattler, M.</span><span> </span><span class="NLM_article-title">Targeting mutated tyrosine kinases in the therapy of myeloid leukaemias</span> <span class="citation_source-journal">Expert Opin. Ther. Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">221</span><span class="NLM_x">–</span> <span class="NLM_lpage">239</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm200712h&amp;key=10.1517%2F14728222.8.3.221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm200712h&amp;key=15161429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm200712h&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkt1Ghu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2004&pages=221-239&author=L.+Banerjiauthor=M.+Sattler&title=Targeting+mutated+tyrosine+kinases+in+the+therapy+of+myeloid+leukaemias"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting mutated tyrosine kinases in the therapy of myeloid leukaemias</span></div><div class="casAuthors">Banerji, Lolita; Sattler, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">221-239</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Myeloid leukemias are frequently assocd. with translocations and mutations of tyrosine kinase genes.  The products of these oncogenes, including BCR-ABL, TEL-PDGFR, Flt3 and c-Kit, have elevated tyrosine kinase activity and transform hematopoietic cells, mainly by augmentation of proliferation and enhanced viability.  Activated ABL kinases are assocd. with chronic myeloid leukemia.  Mutations in platelet-derived growth factor receptor β are assocd. with chronic myelomonocytic leukemia.  Flt3 or c-Kit cooperate with other types of oncogenes to create fully transformed acute leukemias.  Elevated activity of these tyrosine kinases is crucial for transformation, thus making the kinase domain an ideal target for therapeutic intervention.  Tyrosine kinase inhibitors for various kinases are currently being evaluated in clin. trials and are potentially useful therapeutic agents in myeloid leukemias.  Here, the authors review the signaling activities, mechanism of transformation and therapeutic targeting of several tyrosine kinase oncogenes important in myeloid leukemias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkIyhaSO7b1bVg90H21EOLACvtfcHk0lgj_AoLG1knDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkt1Ghu70%253D&md5=f96061c0ac5c290bc5a0cd2b983807b7</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1517%2F14728222.8.3.221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.8.3.221%26sid%3Dliteratum%253Aachs%26aulast%3DBanerji%26aufirst%3DL.%26aulast%3DSattler%26aufirst%3DM.%26atitle%3DTargeting%2520mutated%2520tyrosine%2520kinases%2520in%2520the%2520therapy%2520of%2520myeloid%2520leukaemias%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2004%26volume%3D8%26spage%3D221%26epage%3D239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Stacchini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fubini, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Severino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanavio, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aglietta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piacibello, W.</span><span> </span><span class="NLM_article-title">Expression of type III receptor tyrosine kinases FLT3 and KIT and responses to their ligands by acute myeloid leukemia blasts</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">1584</span><span class="NLM_x">–</span> <span class="NLM_lpage">1591</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm200712h&amp;key=8847893" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm200712h&amp;key=1%3ACAS%3A280%3ADyaK28vgsVeltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1996&pages=1584-1591&issue=10&author=A.+Stacchiniauthor=L.+Fubiniauthor=A.+Severinoauthor=F.+Sanavioauthor=M.+Agliettaauthor=W.+Piacibello&title=Expression+of+type+III+receptor+tyrosine+kinases+FLT3+and+KIT+and+responses+to+their+ligands+by+acute+myeloid+leukemia+blasts"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of type III receptor tyrosine kinases FLT3 and KIT and responses to their ligands by acute myeloid leukemia blasts</span></div><div class="casAuthors">Stacchini A; Fubini L; Severino A; Sanavio F; Aglietta M; Piacibello W</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1584-91</span>
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    </div><div class="casAbstract">The stem cell tyrosine kinase 1 (STK1) protein is the human homologue of the murine FLT3 gene product, a receptor belonging to the FMS/KIT family.  FLT3 and KIT with their ligands control the growth and differentiation of early human hemopoietic cells.  In the present study, 16 cases of acute myeloid leukemia (AML) were examined by flow cytometry for cell surface expression of FLT3 and KIT receptors.  All cases were also tested for their proliferative response to human FLT3 ligand (FL) and KIT ligand (KL) and for colony formation in the presence of single or associated cytokines.  Among 16 AML cases tested, 10/16 expressed FLT3 receptor and 12/16 expressed KIT receptor, without any correlation with FAB subtype.  FL and KL stimulated the proliferation of leukemic blasts in 11/16 AML cases (including five FLT3 or KIT receptor-negative cases), with an additive effect when added simultaneously.  By contrast, some receptor-expressing AMLs did not display significant proliferative responses to their respective ligands.  FL and KL as single factors induced or significantly increased the colony formation by clonogenic precursor cells respectively in eight and six of 13 cases tested.  In some cases growth factor association significantly enhanced colony growth.  Taken together these observations provide evidence that the pattern of FLT3 and KIT receptor expression is extremely variable among the AMLs and that receptor presence is not necessarily combined with proliferative and clonogenic response or vice versa.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTHFEG53WGqAIJKJbLTgsvCfW6udTcc2eaovwS_lmw6YLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK28vgsVeltw%253D%253D&md5=ec4bb7977b25849a6eaec661d94d23eb</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStacchini%26aufirst%3DA.%26aulast%3DFubini%26aufirst%3DL.%26aulast%3DSeverino%26aufirst%3DA.%26aulast%3DSanavio%26aufirst%3DF.%26aulast%3DAglietta%26aufirst%3DM.%26aulast%3DPiacibello%26aufirst%3DW.%26atitle%3DExpression%2520of%2520type%2520III%2520receptor%2520tyrosine%2520kinases%2520FLT3%2520and%2520KIT%2520and%2520responses%2520to%2520their%2520ligands%2520by%2520acute%2520myeloid%2520leukemia%2520blasts%26jtitle%3DLeukemia%26date%3D1996%26volume%3D10%26issue%3D10%26spage%3D1584%26epage%3D1591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Kiyoi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoe, T.</span><span> </span><span class="NLM_article-title">FLT3 mutations in acute myeloid leukemia</span> <span class="citation_source-journal">Methods Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">125</span><span class="NLM_x">, </span> <span class="NLM_fpage">189</span><span class="NLM_x">–</span> <span class="NLM_lpage">197</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm200712h&amp;key=16502586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm200712h&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFyqtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2006&pages=189-197&author=H.+Kiyoiauthor=T.+Naoe&title=FLT3+mutations+in+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 mutations in acute myeloid leukemia</span></div><div class="casAuthors">Kiyoi, Hitoshi; Naoe, Tomoki</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">Myeloid Leukemia</span>),
    <span class="NLM_cas:pages">189-197</span>CODEN:
                <span class="NLM_cas:coden">MMMEFN</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">A review.  The prevalence of an internal tandem duplication (ITD) of the juxtamembrane domain-coding sequence and a missense mutation of D835 within the kinase domain of the FLT3 gene is 15-35% and 5-10% of adults with acute myeloid leukemia (AML), resp.  In addn., point mutations, deletions, and insertions have been found in the juxtamembrane domain and in the other codons within the kinase domain, though these are less common.  Several large-scale studies in well-documented patients published to date have demonstrated that FLT3 mutations are strongly assocd. with a poor prognosis and a high leukemia cell count in patients with AML, suggesting that FLT3 mutations are involved in disease progression.  Because the detection of FLT3 mutations is fast, easy, and inexpensive, mutation anal. should be performed as a routine test.  This chapter describes methods for detecting ITD and D835 mutations in the FLT3 gene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYmCy3nijk3bVg90H21EOLACvtfcHk0lgYdOCH54T7sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFyqtb8%253D&md5=21b20ab38e23dcbf607640e787e07a35</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKiyoi%26aufirst%3DH.%26aulast%3DNaoe%26aufirst%3DT.%26atitle%3DFLT3%2520mutations%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DMethods%2520Mol.%2520Med.%26date%3D2006%26volume%3D125%26spage%3D189%26epage%3D197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Nakao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokota, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaneko, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horiike, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kashima, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sonoda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujimoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Misawa, S.</span><span> </span><span class="NLM_article-title">Internal tandem duplication of the flt3 gene found in acute myeloid leukemia</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">1911</span><span class="NLM_x">–</span> <span class="NLM_lpage">1918</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm200712h&amp;key=8946930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm200712h&amp;key=1%3ACAS%3A280%3ADyaK2s7gt1Kqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1996&pages=1911-1918&issue=12&author=M.+Nakaoauthor=S.+Yokotaauthor=T.+Iwaiauthor=H.+Kanekoauthor=S.+Horiikeauthor=K.+Kashimaauthor=Y.+Sonodaauthor=T.+Fujimotoauthor=S.+Misawa&title=Internal+tandem+duplication+of+the+flt3+gene+found+in+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Internal tandem duplication of the flt3 gene found in acute myeloid leukemia</span></div><div class="casAuthors">Nakao M; Yokota S; Iwai T; Kaneko H; Horiike S; Kashima K; Sonoda Y; Fujimoto T; Misawa S</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1911-8</span>
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    </div><div class="casAbstract">We analyzed mRNA expression of the flt3 gene in 30 patients with acute myeloid leukemia (AML) and 50 with acute lymphoblastic leukemia (ALL).  Using reverse transcriptase-polymerase chain reaction (RT-PCR), expression of flt3 was observed in 61 patients; 22 (73%) with AML and 39 (78%) with ALL.  Among these, five patients with AML (one M2, two M4, and two M5) showed unexpected longer transcripts with a primer combination which could amplify the transmembrane (TM) domain through the juxtamembrane (JM) domain.  For those patients who expressed flt3 mRNA, the extracellular domain of the flt3 gene was also examined by RT-PCR, but no length abnormality was seen in this region.  We further analyzed the TM domain through the second tyrosine kinase domain by genomic amplifications.  The five patients who showed aberrant flt3 transcripts exhibited abnormal longer PCR products in addition to the germline products at a region corresponding to the JM through the first TK (TK1) domains.  Sequence analyses of the abnormal RT-PCR products demonstrated that partial sequences were tandemly duplicated.  Because all these altered transcripts were in-frame, deduced protein products could be expected.  Sequence analyses of the genomic DNA revealed that three of the five patients showed a simple internal duplication within exon 11; one had an internal duplication (26 bp) with a 4-bp insertion; and in the fifth patient, a 136-bp sequence from the 3' part of exon 11 to intron 11 and the first 16-bp sequence of exon 12 were each duplicated with 1-bp insertion.  In order to confirm the tumor specificity of these alterations, DNA samples obtained at complete remission were also analyzed in the three patients harboring an flt3 duplication, but no abnormal PCR product other than germline was detected in any of the samples.  Our results suggest that an internal tandem duplication at the JM/TK1 domains of the flt3 gene is a somatic change detected preferentially in AML, possibly containing a monocytic component.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQL5G2hUkeODSA3UY9EwTNrfW6udTcc2eaovwS_lmw6YLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2s7gt1Kqsg%253D%253D&md5=da0c7f21e6c4daf68bd4b1ae38a92891</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNakao%26aufirst%3DM.%26aulast%3DYokota%26aufirst%3DS.%26aulast%3DIwai%26aufirst%3DT.%26aulast%3DKaneko%26aufirst%3DH.%26aulast%3DHoriike%26aufirst%3DS.%26aulast%3DKashima%26aufirst%3DK.%26aulast%3DSonoda%26aufirst%3DY.%26aulast%3DFujimoto%26aufirst%3DT.%26aulast%3DMisawa%26aufirst%3DS.%26atitle%3DInternal%2520tandem%2520duplication%2520of%2520the%2520flt3%2520gene%2520found%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeukemia%26date%3D1996%26volume%3D10%26issue%3D12%26spage%3D1911%26epage%3D1918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Quentmeier, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reinhardt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaborski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drexler, H. G.</span><span> </span><span class="NLM_article-title">FLT3 mutations in acute myeloid leukemia cell lines</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">120</span><span class="NLM_x">–</span> <span class="NLM_lpage">124</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2003&pages=120-124&author=H.+Quentmeierauthor=J.+Reinhardtauthor=M.+Zaborskiauthor=H.+G.+Drexler&title=FLT3+mutations+in+acute+myeloid+leukemia+cell+lines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DQuentmeier%26aufirst%3DH.%26aulast%3DReinhardt%26aufirst%3DJ.%26aulast%3DZaborski%26aufirst%3DM.%26aulast%3DDrexler%26aufirst%3DH.%2BG.%26atitle%3DFLT3%2520mutations%2520in%2520acute%2520myeloid%2520leukemia%2520cell%2520lines%26jtitle%3DLeukemia%26date%3D2003%26volume%3D17%26spage%3D120%26epage%3D124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Yamamoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiyoi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakano, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodera, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyawaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asou, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yagasaki, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimazaki, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akiyama, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saito, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishimura, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Motoji, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shinagawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeshita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saito, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueda, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohno, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoe, T.</span><span> </span><span class="NLM_article-title">Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">2434</span><span class="NLM_x">–</span> <span class="NLM_lpage">2439</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2001&pages=2434-2439&author=Y.+Yamamotoauthor=H.+Kiyoiauthor=Y.+Nakanoauthor=R.+Suzukiauthor=Y.+Koderaauthor=S.+Miyawakiauthor=N.+Asouauthor=K.+Kuriyamaauthor=F.+Yagasakiauthor=C.+Shimazakiauthor=H.+Akiyamaauthor=K.+Saitoauthor=M.+Nishimuraauthor=T.+Motojiauthor=K.+Shinagawaauthor=A.+Takeshitaauthor=H.+Saitoauthor=R.+Uedaauthor=R.+Ohnoauthor=T.+Naoe&title=Activating+mutation+of+D835+within+the+activation+loop+of+FLT3+in+human+hematologic+malignancies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DY.%26aulast%3DKiyoi%26aufirst%3DH.%26aulast%3DNakano%26aufirst%3DY.%26aulast%3DSuzuki%26aufirst%3DR.%26aulast%3DKodera%26aufirst%3DY.%26aulast%3DMiyawaki%26aufirst%3DS.%26aulast%3DAsou%26aufirst%3DN.%26aulast%3DKuriyama%26aufirst%3DK.%26aulast%3DYagasaki%26aufirst%3DF.%26aulast%3DShimazaki%26aufirst%3DC.%26aulast%3DAkiyama%26aufirst%3DH.%26aulast%3DSaito%26aufirst%3DK.%26aulast%3DNishimura%26aufirst%3DM.%26aulast%3DMotoji%26aufirst%3DT.%26aulast%3DShinagawa%26aufirst%3DK.%26aulast%3DTakeshita%26aufirst%3DA.%26aulast%3DSaito%26aufirst%3DH.%26aulast%3DUeda%26aufirst%3DR.%26aulast%3DOhno%26aufirst%3DR.%26aulast%3DNaoe%26aufirst%3DT.%26atitle%3DActivating%2520mutation%2520of%2520D835%2520within%2520the%2520activation%2520loop%2520of%2520FLT3%2520in%2520human%2520hematologic%2520malignancies%26jtitle%3DBlood%26date%3D2001%26volume%3D97%26spage%3D2434%26epage%3D2439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Beran, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luthra, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estey, E.</span><span> </span><span class="NLM_article-title">FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotype</span> <span class="citation_source-journal">Leuk. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">547</span><span class="NLM_x">–</span> <span class="NLM_lpage">550</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm200712h&amp;key=10.1016%2Fj.leukres.2003.09.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm200712h&amp;key=15120929" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm200712h&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjs1eqtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2004&pages=547-550&author=M.+Beranauthor=R.+Luthraauthor=H.+Kantarjianauthor=E.+Estey&title=FLT3+mutation+and+response+to+intensive+chemotherapy+in+young+adult+and+elderly+patients+with+normal+karyotype"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotype</span></div><div class="casAuthors">Beran, Miloslav; Luthra, Rajyalakshmi; Kantarjian, Hagop; Estey, Elihu</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">547-550</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">The prognostic impact of FLT3 mutations on the outcome of patients with diploid AML, treated with intensive chemotherapy, was analyzed.  In 176 patients, the frequency of single ITD was 30% (<61 yr: 37%, >60 yr: 23%), single D835 mutation 2.3%, and both 2.3%.  There was no assocn. between ITD and CR rate.  ITD-pos. patients <61 yr had a higher frequency of resistant disease.  ITD was adversely assocd. with CR duration and survival in both younger and elderly patients treated with comparable chemotherapy but the effect was less in the elderly.  Presence of both ITD and D835 heralded the least favorable outcome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOs5WEiyytUbVg90H21EOLACvtfcHk0lgcFIQbFhuPLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjs1eqtbs%253D&md5=c3ca274f61e2cad6cd3ac694f4b38e7f</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2003.09.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2003.09.016%26sid%3Dliteratum%253Aachs%26aulast%3DBeran%26aufirst%3DM.%26aulast%3DLuthra%26aufirst%3DR.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DEstey%26aufirst%3DE.%26atitle%3DFLT3%2520mutation%2520and%2520response%2520to%2520intensive%2520chemotherapy%2520in%2520young%2520adult%2520and%2520elderly%2520patients%2520with%2520normal%2520karyotype%26jtitle%3DLeuk.%2520Res.%26date%3D2004%26volume%3D28%26spage%3D547%26epage%3D550" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Kottaridis, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gale, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linch, D. C.</span><span> </span><span class="NLM_article-title">Prognostic implications of the presence of FLT3 mutations in patients with acute myeloid leukemia</span> <span class="citation_source-journal">Leuk. Lymphoma</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">905</span><span class="NLM_x">–</span> <span class="NLM_lpage">913</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm200712h&amp;key=10.1080%2F1042819031000067503" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm200712h&amp;key=12854887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm200712h&amp;key=1%3ACAS%3A528%3ADC%252BD3sXit1yqsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2003&pages=905-913&author=P.+D.+Kottaridisauthor=R.+E.+Galeauthor=D.+C.+Linch&title=Prognostic+implications+of+the+presence+of+FLT3+mutations+in+patients+with+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Prognostic Implications of the Presence of FLT3 Mutations in Patients with Acute Myeloid Leukemia</span></div><div class="casAuthors">Kottaridis, Panagiotis D.; Gale, Rosemary E.; Linch, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia & Lymphoma</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">905-913</span>CODEN:
                <span class="NLM_cas:coden">LELYEA</span>;
        ISSN:<span class="NLM_cas:issn">1042-8194</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Several studies have shown that mutations in the FLT3 gene are common events in AML, with approx. one third of adult patients harboring either an internal tandem duplication in the juxtramembrane domain or a D835 mutation in the kinase domain.  The majority of studies in pediatric and adult AML have shown that FLT3 mutations are powerful prognostic factors predicting for increased relapse risk and adverse overall survival.  Some reports have suggested that loss of the wild type allele might be assocd. with an even worse prognosis.  Changes in the pattern of FLT3 mutations between disease presentation and relapse restrict their value as a marker of minimal residual disease, and have significant implications for therapy.  The optimum treatment for patients with FLT3 mutations remains unknown and large prospective studies are warranted to evaluate the efficacy of various treatment modalities such as bone marrow transplantation and targeted therapy with tyrosine kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQTwjPfq-GmbVg90H21EOLACvtfcHk0ljgqFkAE1jkOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXit1yqsLY%253D&md5=a8e8475402ecf5d5600a0e4ed7a5fdb3</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1080%2F1042819031000067503&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F1042819031000067503%26sid%3Dliteratum%253Aachs%26aulast%3DKottaridis%26aufirst%3DP.%2BD.%26aulast%3DGale%26aufirst%3DR.%2BE.%26aulast%3DLinch%26aufirst%3DD.%2BC.%26atitle%3DPrognostic%2520implications%2520of%2520the%2520presence%2520of%2520FLT3%2520mutations%2520in%2520patients%2520with%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeuk.%2520Lymphoma%26date%3D2003%26volume%3D44%26spage%3D905%26epage%3D913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Cheng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paz, K.</span><span> </span><span class="NLM_article-title">Tandutinib, an oral, small-molecule inhibitor of FLT3 for the treatment of AML and other cancer indications</span> <span class="citation_source-journal">IDrugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">46</span><span class="NLM_x">–</span> <span class="NLM_lpage">56</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm200712h&amp;key=18175263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm200712h&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitV2nsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2008&pages=46-56&issue=1&author=Y.+Chengauthor=K.+Paz&title=Tandutinib%2C+an+oral%2C+small-molecule+inhibitor+of+FLT3+for+the+treatment+of+AML+and+other+cancer+indications"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Tandutinib, an oral, small-molecule inhibitor of FLT3 for the treatment of AML and other cancer indications</span></div><div class="casAuthors">Cheng, Yuan; Paz, Keren</div><div class="citationInfo"><span class="NLM_cas:title">IDrugs</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">46-56</span>CODEN:
                <span class="NLM_cas:coden">IDRUFN</span>;
        ISSN:<span class="NLM_cas:issn">1369-7056</span>.
    
            (<span class="NLM_cas:orgname">Thomson Scientific</span>)
        </div><div class="casAbstract">A review.  An improved understanding of acute myelogenous leukemia (AML) over the past two decades has led to a characterization of assocd. recurring cytogenetic abnormalities.  AML is often driven by the overexpression or constitutive activation of receptor tyrosine kinases such as Fms-like tyrosine kinase 3 (FLT3), which serves as a good therapeutic target.  Millennium Pharmaceuticals Inc's tandutinib (MLN-518) is an orally active inhibitor of FLT3 kinase and family members PDGFRβ and c-Kit.  Tandutinib inhibited FLT3 phosphorylation, downstream signaling and malignant growth in vitro and in animal models.  The drug exhibited limited activity as a single agent in phase I and II clin. trials in patients with AML and myelodysplastic syndrome, but displayed promising antileukemic activity (90% complete remissions) in a phase I/II trial in patients with newly diagnosed AML when administered in combination with cytarabine and daunorubicin.  Phase II clin. trials for tandutinib are ongoing in patients with AML or renal cell carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVck99MEofJbVg90H21EOLACvtfcHk0ljgqFkAE1jkOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitV2nsbo%253D&md5=aee8839e19069c5193d364832a9797e5</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DPaz%26aufirst%3DK.%26atitle%3DTandutinib%252C%2520an%2520oral%252C%2520small-molecule%2520inhibitor%2520of%2520FLT3%2520for%2520the%2520treatment%2520of%2520AML%2520and%2520other%2520cancer%2520indications%26jtitle%3DIDrugs%26date%3D2008%26volume%3D11%26issue%3D1%26spage%3D46%26epage%3D56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Levis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tse, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baldwin, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones-Brolin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dionne, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, D. A.</span><span> </span><span class="NLM_article-title">FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">3885</span><span class="NLM_x">–</span> <span class="NLM_lpage">3891</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=3885-3891&issue=11&author=M.+Levisauthor=K.+F.+Tseauthor=R.+Zhengauthor=B.+R.+Baldwinauthor=B.+D.+Smithauthor=S.+Jones-Brolinauthor=B.+Ruggeriauthor=C.+Dionneauthor=D.+A.+Small&title=FLT3-targeted+tyrosine+kinase+inhibitor+is+cytotoxic+to+leukemia+cells+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DTse%26aufirst%3DK.%2BF.%26aulast%3DZheng%26aufirst%3DR.%26aulast%3DBaldwin%26aufirst%3DB.%2BR.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DJones-Brolin%26aufirst%3DS.%26aulast%3DRuggeri%26aufirst%3DB.%26aulast%3DDionne%26aufirst%3DC.%26aulast%3DSmall%26aufirst%3DD.%2BA.%26atitle%3DFLT3-targeted%2520tyrosine%2520kinase%2520inhibitor%2520is%2520cytotoxic%2520to%2520leukemia%2520cells%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBlood%26date%3D2002%26volume%3D99%26issue%3D11%26spage%3D3885%26epage%3D3891" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">O'Farrell, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abrams, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ngai, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louie, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yee, K. W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Town, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smolich, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manning, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherrington, J. M.</span><span> </span><span class="NLM_article-title">SU11248 is a novel FLT3 tyrosine kinase with potent activity in vitro and in vivo</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">3597</span><span class="NLM_x">–</span> <span class="NLM_lpage">3605</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2003&pages=3597-3605&issue=9&author=A.+M.+O%27Farrellauthor=T.+J.+Abramsauthor=H.+A.+Yuenauthor=T.+J.+Ngaiauthor=S.+G.+Louieauthor=K.+W.+H.+Yeeauthor=L.+M.+Wongauthor=W.+Hongauthor=L.+B.+Leeauthor=A.+Townauthor=B.+D.+Smolichauthor=W.+C.+Manningauthor=L.+J.+Murrayauthor=M.+C.+Heinrichauthor=J.+M.+Cherrington&title=SU11248+is+a+novel+FLT3+tyrosine+kinase+with+potent+activity+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%2527Farrell%26aufirst%3DA.%2BM.%26aulast%3DAbrams%26aufirst%3DT.%2BJ.%26aulast%3DYuen%26aufirst%3DH.%2BA.%26aulast%3DNgai%26aufirst%3DT.%2BJ.%26aulast%3DLouie%26aufirst%3DS.%2BG.%26aulast%3DYee%26aufirst%3DK.%2BW.%2BH.%26aulast%3DWong%26aufirst%3DL.%2BM.%26aulast%3DHong%26aufirst%3DW.%26aulast%3DLee%26aufirst%3DL.%2BB.%26aulast%3DTown%26aufirst%3DA.%26aulast%3DSmolich%26aufirst%3DB.%2BD.%26aulast%3DManning%26aufirst%3DW.%2BC.%26aulast%3DMurray%26aufirst%3DL.%2BJ.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DCherrington%26aufirst%3DJ.%2BM.%26atitle%3DSU11248%2520is%2520a%2520novel%2520FLT3%2520tyrosine%2520kinase%2520with%2520potent%2520activity%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBlood%26date%3D2003%26volume%3D101%26issue%3D9%26spage%3D3597%26epage%3D3605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Mori, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreef, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravandi, F.</span><span> </span><span class="NLM_article-title">Potential role of sorafenib in the treatment of acute myeloid leukemia</span> <span class="citation_source-journal">Leuk. Lymphoma</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">2246</span><span class="NLM_x">–</span> <span class="NLM_lpage">2255</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm200712h&amp;key=10.1080%2F10428190802510349" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm200712h&amp;key=19052971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm200712h&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVKjsr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2008&pages=2246-2255&issue=12&author=S.+Moriauthor=J.+Cortesauthor=H.+Kantarjianauthor=W.+Zhangauthor=M.+Andreefauthor=F.+Ravandi&title=Potential+role+of+sorafenib+in+the+treatment+of+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Potential role of sorafenib in the treatment of acute myeloid leukemia</span></div><div class="casAuthors">Mori, Shahram; Cortes, Jorge; Kantarjian, Hagop; Zhang, Weiguo; Andreef, Michael; Ravandi, Farhad</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia & Lymphoma</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2246-2255</span>CODEN:
                <span class="NLM_cas:coden">LELYEA</span>;
        ISSN:<span class="NLM_cas:issn">1042-8194</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  The identification of aberrant cellular pathways and dysfunctional mols. important in neoplastic transformation has begun to provide us with a no. of targets for drug development.  It is likely that many of these agents will be incorporated into our existing treatment strategies that include cytotoxic agents.  Sorafenib, a multi-kinase inhibitor has been approved in the United States for the treatment of renal cell carcinoma as well as hepatocellular cancer.  Its potential role in hematol. malignancies, particularly acute myeloid leukemia (AML) is under evaluation.  Here we describe the biol. pathways in AML that are the potential targets of sorafenib action and discuss the early clin. data with the agent in solid tumors and AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmEcMC8shxmbVg90H21EOLACvtfcHk0lhejLaD_6XBZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVKjsr%252FN&md5=0fb05e7866581d2f4f5c4f70204756c5</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1080%2F10428190802510349&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10428190802510349%26sid%3Dliteratum%253Aachs%26aulast%3DMori%26aufirst%3DS.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DAndreef%26aufirst%3DM.%26aulast%3DRavandi%26aufirst%3DF.%26atitle%3DPotential%2520role%2520of%2520sorafenib%2520in%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeuk.%2520Lymphoma%26date%3D2008%26volume%3D49%26issue%3D12%26spage%3D2246%26epage%3D2255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Kindler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipka, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, T.</span><span> </span><span class="NLM_article-title">FLT3 as a therapeutic target: still challenging after all these years</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x"> (</span><span class="NLM_issue">24</span><span class="NLM_x">) </span> <span class="NLM_fpage">5089</span><span class="NLM_x">–</span> <span class="NLM_lpage">5102</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2010&pages=5089-5102&issue=24&author=T.+Kindlerauthor=D.+B.+Lipkaauthor=T.+Fischer&title=FLT3+as+a+therapeutic+target%3A+still+challenging+after+all+these+years"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKindler%26aufirst%3DT.%26aulast%3DLipka%26aufirst%3DD.%2BB.%26aulast%3DFischer%26aufirst%3DT.%26atitle%3DFLT3%2520as%2520a%2520therapeutic%2520target%253A%2520still%2520challenging%2520after%2520all%2520these%2520years%26jtitle%3DBlood%26date%3D2010%26volume%3D116%26issue%3D24%26spage%3D5089%26epage%3D5102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Pratz, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roboz, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arowojolu, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stine, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiotsu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shudo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akinaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M.</span><span> </span><span class="NLM_article-title">A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">3938</span><span class="NLM_x">–</span> <span class="NLM_lpage">3946</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=3938-3946&author=K.+W.+Pratzauthor=J.+Cortesauthor=G.+J.+Robozauthor=N.+Raoauthor=O.+Arowojoluauthor=A.+Stineauthor=Y.+Shiotsuauthor=A.+Shudoauthor=S.+Akinagaauthor=D.+Smallauthor=J.+E.+Karpauthor=M.+Levis&title=A+pharmacodynamic+study+of+the+FLT3+inhibitor+KW-2449+yields+insight+into+the+basis+for+clinical+response"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPratz%26aufirst%3DK.%2BW.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DRoboz%26aufirst%3DG.%2BJ.%26aulast%3DRao%26aufirst%3DN.%26aulast%3DArowojolu%26aufirst%3DO.%26aulast%3DStine%26aufirst%3DA.%26aulast%3DShiotsu%26aufirst%3DY.%26aulast%3DShudo%26aufirst%3DA.%26aulast%3DAkinaga%26aufirst%3DS.%26aulast%3DSmall%26aufirst%3DD.%26aulast%3DKarp%26aufirst%3DJ.%2BE.%26aulast%3DLevis%26aufirst%3DM.%26atitle%3DA%2520pharmacodynamic%2520study%2520of%2520the%2520FLT3%2520inhibitor%2520KW-2449%2520yields%2520insight%2520into%2520the%2520basis%2520for%2520clinical%2520response%26jtitle%3DBlood%26date%3D2009%26volume%3D113%26spage%3D3938%26epage%3D3946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Stone, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeAngelo, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klimek, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galinsky, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estey, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nimer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grandin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebwohl, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">54</span><span class="NLM_x">–</span> <span class="NLM_lpage">60</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2005&pages=54-60&issue=1&author=R.+M.+Stoneauthor=D.+J.+DeAngeloauthor=V.+Klimekauthor=I.+Galinskyauthor=E.+Esteyauthor=S.+D.+Nimerauthor=W.+Grandinauthor=D.+Lebwohlauthor=Y.+Wangauthor=P.+Cohenauthor=E.+A.+Foxauthor=D.+Neubergauthor=J.+Clarkauthor=D.+G.+Gillilandauthor=J.+D.+Griffin&title=Patients+with+acute+myeloid+leukemia+and+an+activating+mutation+in+FLT3+respond+to+a+small-molecule+FLT3+tyrosine+kinase+inhibitor%2C+PKC412"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DDeAngelo%26aufirst%3DD.%2BJ.%26aulast%3DKlimek%26aufirst%3DV.%26aulast%3DGalinsky%26aufirst%3DI.%26aulast%3DEstey%26aufirst%3DE.%26aulast%3DNimer%26aufirst%3DS.%2BD.%26aulast%3DGrandin%26aufirst%3DW.%26aulast%3DLebwohl%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DFox%26aufirst%3DE.%2BA.%26aulast%3DNeuberg%26aufirst%3DD.%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DPatients%2520with%2520acute%2520myeloid%2520leukemia%2520and%2520an%2520activating%2520mutation%2520in%2520FLT3%2520respond%2520to%2520a%2520small-molecule%2520FLT3%2520tyrosine%2520kinase%2520inhibitor%252C%2520PKC412%26jtitle%3DBlood%26date%3D2005%26volume%3D105%26issue%3D1%26spage%3D54%26epage%3D60" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunawardane, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cramer, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brigham, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belli, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karaman, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pratz, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sprankle, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armstrong, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhagwat, S. S.</span><span> </span><span class="NLM_article-title">AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x"> (</span><span class="NLM_issue">14</span><span class="NLM_x">) </span> <span class="NLM_fpage">2984</span><span class="NLM_x">–</span> <span class="NLM_lpage">2992</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=2984-2992&issue=14&author=P.+P.+Zarrinkarauthor=R.+N.+Gunawardaneauthor=M.+D.+Cramerauthor=M.+F.+Gardnerauthor=D.+Brighamauthor=B.+Belliauthor=M.+W.+Karamanauthor=K.+W.+Pratzauthor=G.+Pallaresauthor=Q.+Chaoauthor=K.+G.+Sprankleauthor=H.+K.+Patelauthor=M.+Levisauthor=R.+C.+Armstrongauthor=J.+Jamesauthor=S.+S.+Bhagwat&title=AC220+is+a+uniquely+potent+and+selective+inhibitor+of+FLT3+for+the+treatment+of+acute+myeloid+leukemia+%28AML%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DGunawardane%26aufirst%3DR.%2BN.%26aulast%3DCramer%26aufirst%3DM.%2BD.%26aulast%3DGardner%26aufirst%3DM.%2BF.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DBelli%26aufirst%3DB.%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DPratz%26aufirst%3DK.%2BW.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DChao%26aufirst%3DQ.%26aulast%3DSprankle%26aufirst%3DK.%2BG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DArmstrong%26aufirst%3DR.%2BC.%26aulast%3DJames%26aufirst%3DJ.%26aulast%3DBhagwat%26aufirst%3DS.%2BS.%26atitle%3DAC220%2520is%2520a%2520uniquely%2520potent%2520and%2520selective%2520inhibitor%2520of%2520FLT3%2520for%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%2520%2528AML%2529%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26issue%3D14%26spage%3D2984%26epage%3D2992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Dunstan, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rihs, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widmer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dziadulewicz, E. K.</span><span> </span><span class="NLM_article-title">Concise and regiospecific syntheses of tri-substituted 1,2,4-triazoles</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">7983</span><span class="NLM_x">–</span> <span class="NLM_lpage">7986</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1998&pages=7983-7986&author=A.+R.+Dunstanauthor=H.+P.+Weberauthor=G.+Rihsauthor=H.+Widmerauthor=E.+K.+Dziadulewicz&title=Concise+and+regiospecific+syntheses+of+tri-substituted+1%2C2%2C4-triazoles"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDunstan%26aufirst%3DA.%2BR.%26aulast%3DWeber%26aufirst%3DH.%2BP.%26aulast%3DRihs%26aufirst%3DG.%26aulast%3DWidmer%26aufirst%3DH.%26aulast%3DDziadulewicz%26aufirst%3DE.%2BK.%26atitle%3DConcise%2520and%2520regiospecific%2520syntheses%2520of%2520tri-substituted%25201%252C2%252C4-triazoles%26jtitle%3DTetrahedron%2520Lett.%26date%3D1998%26volume%3D39%26spage%3D7983%26epage%3D7986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Davies, R. J.; Forster, C. J.; Arnost, M. J.; Wang, J.</span><span> </span><span class="NLM_article-title">Triazoles useful as inhibitors of protein kinases and their preparation, pharmaceutical compositions, and use for treatment of various disorders</span>, WO 2006047256 A1 20060504.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Davies%2C+R.+J.%3B+Forster%2C+C.+J.%3B+Arnost%2C+M.+J.%3B+Wang%2C+J.+Triazoles+useful+as+inhibitors+of+protein+kinases+and+their+preparation%2C+pharmaceutical+compositions%2C+and+use+for+treatment+of+various+disorders%2C+WO+2006047256+A1+20060504."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DR.%2BJ.%26atitle%3DTriazoles%2520useful%2520as%2520inhibitors%2520of%2520protein%2520kinases%2520and%2520their%2520preparation%252C%2520pharmaceutical%2520compositions%252C%2520and%2520use%2520for%2520treatment%2520of%2520various%2520disorders" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Heidary, D. K.; Huang, G.; Ma, J.; Boucher, D.; Forster, C.; Grey, R.; Xu, J.; Chen, G.; Zhou, J.; Namchuk, M.; Yao, M.; Stack, J.; Ball, E. D.; Davies, R. J.; Henkel, G.</span><span> </span><span class="NLM_article-title">VX-322: A Novel Dual Receptor Tyrosine Kinase Inhibitor for the Treatment of AML</span>. J. Med. Chem.<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">, </span>not supplied. </span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=D.+K.+Heidary&author=G.+Huang&author=J.+Ma&author=D.+Boucher&author=C.+Forster&author=R.+Grey&author=J.+Xu&author=G.+Chen&author=J.+Zhou&author=M.+Namchuk&author=M.+Yao&author=J.+Stack&author=E.+D.+Ball&author=R.+J.+Davies&author=G.+Henkel&title=VX-322%3A+A+Novel+Dual+Receptor+Tyrosine+Kinase+Inhibitor+for+the+Treatment+of+AML"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DHeidary%26aufirst%3DD.%2BK.%26atitle%3DVX-322%253A%2520A%2520Novel%2520Dual%2520Receptor%2520Tyrosine%2520Kinase%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520AML%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="note"><p class="first last">Primary leukemic blasts isolated from peripheral blood of AML patients were characterized for FLT3 mutations by RT-PCR and for cell-surface expression of FLT3, KIT, and the hematopoietic precursor marker CD34 by flow cytometry. FLT3 and KIT-positive blasts from four patients were incubated for 72 h with compound in the presence of human serum, FL, SCF, and GM-CSF, and then, viability was measured by ATP-luciferase assay.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">McTigue, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wickersham, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinko, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parast, C. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tempczyk-Russell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gehring, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kan, C.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villafranca, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Appelt, K.</span><span> </span><span class="NLM_article-title">Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: A key enzyme in angiogenesis</span> <span class="citation_source-journal">Structure</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">319</span><span class="NLM_x">–</span> <span class="NLM_lpage">330</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1999&pages=319-330&author=M.+A.+McTigueauthor=J.+A.+Wickershamauthor=C.+Pinkoauthor=R.+E.+Showalterauthor=C.+V.+Parastauthor=A.+Tempczyk-Russellauthor=M.+R.+Gehringauthor=B.+Mroczkowskiauthor=C.-C.+Kanauthor=J.+E.+Villafrancaauthor=K.+Appelt&title=Crystal+structure+of+the+kinase+domain+of+human+vascular+endothelial+growth+factor+receptor+2%3A+A+key+enzyme+in+angiogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMcTigue%26aufirst%3DM.%2BA.%26aulast%3DWickersham%26aufirst%3DJ.%2BA.%26aulast%3DPinko%26aufirst%3DC.%26aulast%3DShowalter%26aufirst%3DR.%2BE.%26aulast%3DParast%26aufirst%3DC.%2BV.%26aulast%3DTempczyk-Russell%26aufirst%3DA.%26aulast%3DGehring%26aufirst%3DM.%2BR.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DKan%26aufirst%3DC.-C.%26aulast%3DVillafranca%26aufirst%3DJ.%2BE.%26aulast%3DAppelt%26aufirst%3DK.%26atitle%3DCrystal%2520structure%2520of%2520the%2520kinase%2520domain%2520of%2520human%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%25202%253A%2520A%2520key%2520enzyme%2520in%2520angiogenesis%26jtitle%3DStructure%26date%3D1999%26volume%3D3%26spage%3D319%26epage%3D330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Griffith, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faerman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swenson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wynn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippke, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saxena, K.</span><span> </span><span class="NLM_article-title">The Structural Basis for Autoinhibition of FLT3 by the Juxtamembrane Domain</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">178</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm200712h&amp;key=10.1016%2FS1097-2765%2803%2900505-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm200712h&amp;key=14759363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm200712h&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFOiu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2004&pages=169-178&author=J.+Griffithauthor=J.+Blackauthor=C.+Faermanauthor=L.+Swensonauthor=M.+Wynnauthor=F.+Luauthor=J.+Lippkeauthor=K.+Saxena&title=The+Structural+Basis+for+Autoinhibition+of+FLT3+by+the+Juxtamembrane+Domain"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">The structural basis for autoinhibition of FLT3 by the juxtamembrane domain</span></div><div class="casAuthors">Griffith, James; Black, James; Faerman, Carlos; Swenson, Lora; Wynn, Michael; Lu, Fan; Lippke, Judith; Saxena, Kumkum</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">169-178</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">FLT3 is a type III receptor tyrosine kinase that is thought to play a key role in hematopoiesis.  Certain classes of FLT3 mutations cause constitutively activated forms of the receptor that are found in significant nos. of patients with acute myelogenous leukemia (AML).  The mutations occur either in the activation loop, for example, as point mutations of Asp835 or as internal tandem duplication (ITD) sequences in the juxtamembrane (JM) domain.  To further understand the nature of FLT3 autoinhibition and regulation, we have detd. the crystal structure of the autoinhibited form of FLT3.  This structure shows the autoinhibitory conformation of a complete JM domain in this class of receptor tyrosine kinases.  The detailed inhibitory mechanism of the JM domain is revealed, which is likely utilized by other members of type III receptor tyrosine kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJAabT6TBxpLVg90H21EOLACvtfcHk0ljjTVZatOWfNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFOiu7g%253D&md5=d1df4a37aac59f5b59ca242fc8ccd6da</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2FS1097-2765%2803%2900505-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1097-2765%252803%252900505-7%26sid%3Dliteratum%253Aachs%26aulast%3DGriffith%26aufirst%3DJ.%26aulast%3DBlack%26aufirst%3DJ.%26aulast%3DFaerman%26aufirst%3DC.%26aulast%3DSwenson%26aufirst%3DL.%26aulast%3DWynn%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DF.%26aulast%3DLippke%26aufirst%3DJ.%26aulast%3DSaxena%26aufirst%3DK.%26atitle%3DThe%2520Structural%2520Basis%2520for%2520Autoinhibition%2520of%2520FLT3%2520by%2520the%2520Juxtamembrane%2520Domain%26jtitle%3DMol.%2520Cell%26date%3D2004%26volume%3D13%26spage%3D169%26epage%3D178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span> <span class="citation_source-book">Molecular Operating Environment</span> (MOE, version 2002.03); <span class="NLM_publisher-name">Chemical Computing Group</span>: <span class="NLM_publisher-loc">Montreal, PQ, Canada</span>,<span class="NLM_x"> </span><span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Molecular+Operating+Environment+%28MOE%2C+version+2002.03%29%3B+Chemical+Computing+Group%3A+Montreal%2C+PQ%2C+Canada%2C+2002."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DMolecular%2520Operating%2520Environment%26pub%3DChemical%2520Computing%2520Group%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1VR2" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1VR2','PDB','1VR2'); return false;">PDB: 1VR2</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1RJB" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1RJB','PDB','1RJB'); return false;">PDB: 1RJB</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i20"><a href="/doi/suppl/10.1021/jm200712h">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_86574"></div></div></div></div></div><hr /></hr><p class="last"><sup>1</sup>H NMR and MS spectral data for all of the final compounds. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm200712h/suppl_file/jm200712h_si_001.pdf">jm200712h_si_001.pdf (124.17 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm200712h&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Fjm200712h%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2011.54.issue-20%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm200712h" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66797c34ff03d1a7","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
